US20230390340A1 - Gene therapy - Google Patents
Gene therapy Download PDFInfo
- Publication number
- US20230390340A1 US20230390340A1 US18/086,719 US202218086719A US2023390340A1 US 20230390340 A1 US20230390340 A1 US 20230390340A1 US 202218086719 A US202218086719 A US 202218086719A US 2023390340 A1 US2023390340 A1 US 2023390340A1
- Authority
- US
- United States
- Prior art keywords
- ids
- sequence
- apoeii
- nucleic acid
- mps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001415 gene therapy Methods 0.000 title claims description 13
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims abstract description 326
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims abstract description 324
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims abstract description 119
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 63
- 210000000130 stem cell Anatomy 0.000 claims abstract description 62
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 53
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 53
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 101710095339 Apolipoprotein E Proteins 0.000 claims abstract description 25
- 102100029470 Apolipoprotein E Human genes 0.000 claims abstract description 25
- 230000007812 deficiency Effects 0.000 claims abstract description 23
- 238000011161 development Methods 0.000 claims abstract description 21
- 238000010606 normalization Methods 0.000 claims abstract description 20
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims abstract description 15
- 210000004556 brain Anatomy 0.000 claims description 67
- 239000013598 vector Substances 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 39
- 125000005647 linker group Chemical group 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 230000008499 blood brain barrier function Effects 0.000 claims description 23
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000002950 deficient Effects 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 239000013603 viral vector Substances 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 9
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 9
- 230000002463 transducing effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 20
- 229920001184 polypeptide Polymers 0.000 abstract description 19
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 description 87
- 241000699670 Mus sp. Species 0.000 description 87
- 102000004190 Enzymes Human genes 0.000 description 86
- 229940088598 enzyme Drugs 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 58
- 229920002971 Heparan sulfate Polymers 0.000 description 47
- 230000000694 effects Effects 0.000 description 45
- 210000002381 plasma Anatomy 0.000 description 35
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 21
- 230000002132 lysosomal effect Effects 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 17
- 238000012937 correction Methods 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 description 13
- 102000000853 LDL receptors Human genes 0.000 description 13
- 108010001831 LDL receptors Proteins 0.000 description 13
- 208000015439 Lysosomal storage disease Diseases 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 13
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 150000002016 disaccharides Chemical class 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 11
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 11
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000004727 amygdala Anatomy 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 102000057422 human IDS Human genes 0.000 description 11
- 230000002093 peripheral effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 101150110586 IDS gene Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 210000002637 putamen Anatomy 0.000 description 10
- 108700012434 CCL3 Proteins 0.000 description 9
- 102000000013 Chemokine CCL3 Human genes 0.000 description 9
- 108010055166 Chemokine CCL5 Proteins 0.000 description 9
- 102000001327 Chemokine CCL5 Human genes 0.000 description 9
- 206010018341 Gliosis Diseases 0.000 description 9
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 9
- 208000037875 astrocytosis Diseases 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 230000003959 neuroinflammation Effects 0.000 description 9
- 230000007341 astrogliosis Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 7
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000000979 retarding effect Effects 0.000 description 7
- 230000031998 transcytosis Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 6
- 101150043413 MYH7 gene Proteins 0.000 description 6
- 101150114487 NPPB gene Proteins 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- 108010022901 Heparin Lyase Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 229960002092 busulfan Drugs 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000004700 cellular uptake Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 210000000337 motor cortex Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000006724 microglial activation Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000000216 zygoma Anatomy 0.000 description 4
- PIGCSKVALLVWKU-UHFFFAOYSA-N 2-Aminoacridone Chemical compound C1=CC=C2C(=O)C3=CC(N)=CC=C3NC2=C1 PIGCSKVALLVWKU-UHFFFAOYSA-N 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
- -1 LRP1 Proteins 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 210000001642 activated microglia Anatomy 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002641 enzyme replacement therapy Methods 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 210000002758 humerus Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000002314 neuroinflammatory effect Effects 0.000 description 3
- 238000000059 patterning Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 231100001055 skeletal defect Toxicity 0.000 description 3
- 230000007596 spatial working memory Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 102100025024 Cation-dependent mannose-6-phosphate receptor Human genes 0.000 description 2
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 2
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 208000023147 Lysosomal storage disease with skeletal involvement Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000002802 cardiorespiratory effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006720 chronic neuroinflammation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000053020 human ApoE Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 208000012251 mucopolysaccharidosis Ih Diseases 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002356 skeleton Anatomy 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000011232 storage material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000878581 Aplysia californica Feeding circuit activating peptides Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000178041 Ceropegia media Species 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000004468 Craniofacial Abnormalities Diseases 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 101000782453 Homo sapiens Vacuolar protein sorting-associated protein 18 homolog Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000040952 LDLR family Human genes 0.000 description 1
- 108091077228 LDLR family Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000713880 Spleen focus-forming virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100035870 Vacuolar protein sorting-associated protein 18 homolog Human genes 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108010006406 heparinase II Proteins 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008086 immune related sensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002046 pro-migratory effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000007342 reactive astrogliosis Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to stem cell gene therapies for the treatment of mucopolysaccharidosis (MPS) II.
- Mucopolysaccharidosis type II (MPS II, OMIM #309900), or Hunter syndrome, is a paediatric X-linked lysosomal storage disorder caused by mutations in the IDS gene, leading to deficiencies in iduronate-2-sulfatase enzyme (EC 3.1.6.13).
- This IDS enzyme insufficiency affects the catabolism of both heparan sulphate (HS) and dermatan sulphate, subsequently leading to their unregulated accumulation in the lysosomal compartment of all cells (1).
- HS heparan sulphate
- MPS II affects 1.3 per 100,000 male live births (2-4) and has historically been classified as either attenuated or severe.
- MPS II is a chronic and progressive multi-system disease affecting a multitude of organs such as the brain, heart, skeleton and joints.
- Clinical manifestations in the milder forms of MPS II include severe skeletal abnormalities, known as dysostosis multiplex, short stature, joint stiffness, and hepatosplenomegaly, accompanied by cardiorespiratory symptoms (4, 5).
- Severe MPS II additionally features progressive neurodegeneration, followed by death in teenage years due to obstructive airway disease and cardiac failure (4, 6, 7).
- Enzyme replacement therapy where exogenous replacement enzyme is delivered intravenously and internalised by cells using the mannose-6-phosphate receptor, has been used to treat the somatic symptoms in MPS II patients regardless of disease severity (8, 9).
- enzyme circulating in the bloodstream is prevented from reaching the CNS by the blood-brain barrier (BBB), considerably reducing therapeutic benefits for the two-thirds of MPS II patients that are cognitively affected.
- severe anaphylactic reactions to the replacement enzyme have been reported (9, 10), as well as neutralizing antibodies to the enzyme (11), which may decrease efficacy of the treatment (12).
- Allogeneic stem cell transplantation although recommended to treat neurological symptoms in MPS I Hurler (16-18), has been highly variable in treating the CNS in MPS II and is associated with high rates of morbidity and mortality primarily caused by rejection and graft-versus-host disease (19, 20). It has been suggested that the level of enzyme delivered from an allogeneic transplant, although sufficient to clear primary storage material in peripheral organs, may be too low in the brain and is therefore the limiting factor for complete neurological correction (21, 22).
- HSPCs haematopoietic stem and progenitor cells
- the primary hurdle in treating the neuropathology of diseases that involve the CNS is to bypass the BBB.
- One such strategy is to target proteins to translocate to the CNS via a process known as transcytosis, which exploits receptors located on the BBB surface, such as the transferrin receptor (TfR) and low-density lipoprotein receptor (LDLR) (27).
- the LDLR family are cell-surface receptors that bind alipoprotein (Apo) complexes and target them to the lysosomes (28). Apo complexes bind LDLR on the surface of the BBB and are transcytosed to the abluminal side before being released prior to uptake into neurons and astrocytes (29).
- a number of studies have exploited this minimally-invasive technology by fusing LDLR-binding domain peptides to enzymes of interest, and shown efficient delivery of these chimeric constructs across the BBB in animal models (29-33).
- a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence, or a repeat of part of the ApoEII gene sequence.
- IDS iduronate-2-sulfatase
- ApoEII Apolipoprotein E
- the nucleic acid may further comprise an intervening linker sequence located between the IDS sequence and the ApoEII sequence.
- the IDS sequence may be a codon-optimised sequence of the wild-type IDS sequence.
- the repeat of the ApoEII sequence may be in the form of a tandem repeat.
- the repeat of the ApoEII sequence may be upstream and/or downstream of the IDS sequence.
- the IDS sequence may comprise the sequence according to SEQ ID No. 1 or SEQ ID No. 2 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 1 or SEQ ID No. 2.
- the ApoEII sequence may comprise one or more sequences according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the intervening linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- nucleic acid for use in increasing the plasma level, or stability in plasma, of an enzyme in an individual, the nucleic acid comprising an enzyme gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence.
- ApoEII Apolipoprotein E
- the nucleic acid may further comprise an intervening linker sequence located between the enzyme sequence and the ApoEII sequence.
- the enzyme sequence may be a codon-optimised sequence of the enzyme sequence.
- the repeat of the ApoEII sequence may be in the form of a tandem repeat.
- the repeat of the ApoEII sequence may be upstream and/or downstream of the enzyme sequence.
- the ApoEII sequence may comprise one or more sequences according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the intervening linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the enzyme may be one which is deficient or present at low plasma levels in individuals suffering from lysosomal storage disease.
- the lysosomal storage disease may comprise Mucopolysaccharidosis type II (MPS II).
- the nucleic acid may be a DNA, RNA, cDNA, or PNA and may be recombinant or synthetic. It may be single stranded or double stranded.
- the nucleic acid sequence may be derived by cloning, for example using standard molecular cloning techniques including restriction digestion, ligation, gel electrophoresis (for example as described in Sambrook et al; Molecular Cloning: A laboratory manual , Cold Spring Harbour laboratory Press).
- the nucleic acid sequence may be isolated or amplified using PCR technology. Such technology may employ primers based upon the sequence of the nucleic acid sequence to be amplified. With the sequence information provided, the skilled person can use available cloning techniques to produce a nucleic acid sequence or vector suitable for transduction into a cell.
- the codon optimised IDS nucleic acid sequence may be optimised in a number of ways so as to enable enhanced expression or activity.
- the sequence may have been optimised by selecting codons most common in human cells and/or reducing one or more secondary structures and hairpins which may arise in subsequently formed mRNA and/or inserting a Kozak sequence at the ATG start site.
- the nucleic acid sequence is provided with, in or as part of an expression vector.
- it may be provided as a gene therapy vector, preferably which is suitable for ex vivo transduction in haematopoietic stem and progenitor cells (HSPCs) which are subsequently returned to a mammalian body for expression.
- the vector may be viral or non-viral (e.g. a plasmid).
- Viral vectors include those derived from lentivirus, adenovirus, adenoassociated virus (AAV) including mutated forms, retrovirus, herpes virus, vaccinia virus, MMLV, GaLV, Simian Immune Deficiency Virus (SIV), HIV, pox virus, and SV40.
- a viral vector is preferably replication defective, although it is envisaged that it may be replication deficient, replication competent or conditional.
- a viral vector may typically persist in an extrachromosomal state without integrating into the genome of the target neural cells.
- a preferred viral vector is a lentivirus vector. The viral vector may be modified to delete any non-essential sequences and these will be apparent to the skilled addressee.
- the viral vector has the ability to enter a cell.
- a non-viral vector such as a plasmid may be complexed with an agent to facilitate its uptake by a target cell.
- agents include polycationic agents.
- a delivery system such as a liposome based delivery system may be used.
- the vector for use in the present invention is preferably suitable for use in or ex vivo or in vitro, and is preferably suitable for use in a human. Most preferably, the vector is suitable for transducing haematopoietic stem and progenitor cells (HSPCs) ex vivo.
- HSPCs haematopoietic stem and progenitor cells
- the vector will preferably comprise one or more regulatory sequences to direct expression of the nucleic acid.
- a regulatory sequence may include a promoter operably linked to the IDS and ApoEII nucleic acid sequence, an enhancer, a transcription termination signal, a polyadenylyation sequence, an origin of replication, a nucleic acid restriction site, and a homologous recombination site.
- a vector may also include a selectable marker, for example to determine expression of the vector in a growth system (for example a bacterial cell) or in a target cell.
- operably linked means that the nucleic acid sequence is functionally associated with the sequence to which it is operably linked, such that they are linked in a manner such that they affect the expression or function of one another.
- a nucleic acid sequence operably linked to a promoter will have an expression pattern influenced by the promoter.
- haematopoietic stem and progenitor cells for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs are removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs are administered to the individual.
- IDS iduronate-2-sulfatase
- MPS II Mucopolysaccharidosis type II
- haematopoietic stem and progenitor cells for use in a method of, or for the, treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs administered to the individual.
- IDS iduronate-2-sulfatase
- MPS II Mucopolysaccharidosis type II
- haematopoietic stem and progenitor cells for use in a method of treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the method comprises identifying an individual having said iduronate-2-sulfatase (IDS) deficiency and/or in need of elevated iduronate-2-sulfatase (IDS) levels, removing a portion of HSPCs from the individual, transduced the HSPCs ex vivo with the nucleic acid as herein above described and administering a therapeutically effective amount of the transduced HSPCs to the individual.
- IDDS iduronate-2-sulfatase
- MPS II Mucopolysaccharidosis type II
- haematopoietic stem and progenitor cells for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs formed into a medicament for administration to the patient.
- allogeneic HSPCs may also be utilised, therefore removing the need that the HSPCs be removed from the patient or individual, transduced ex vivo and then administered to the patient or individual.
- Allogeneic HSPCs may be derived from cord blood.
- composition comprising:
- Apolipoprotein E (ApoEII).
- the repeat of ApoEII may be in the form of a tandem repeat.
- the second moiety may be upstream and/or downstream of the first moiety.
- the first and second moiety may have an intervening linker moiety located there between.
- the amino acid sequence of the first moiety may comprise the sequence according to SEQ ID No. 5 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 5.
- the amino acid sequence of the second moiety may comprise one or more sequences according to SEQ ID No. 7 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the amino acid sequence of the intervening linker moiety may comprise the sequence according to SEQ ID No. 8 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- composition for increasing the plasma level, or stability in plasma, of an enzyme comprising:
- Apolipoprotein E (ApoEII).
- the repeat of ApoEII may be in the form of a tandem repeat.
- the second moiety may be upstream and/or downstream of the first moiety.
- the first and second moiety may have an intervening linker moiety located there between.
- the inventors have found that they are able to increase the activity in plasma of enzymes, suggesting potential alterations in enzyme stability and circulation time, secretion or uptake into cells by including a tandem repeat of ApoEII via a linker to the enzyme.
- composition comprising a nucleic acid according to SEQ ID No. 1 or a derivative sequence having at least 95% homology thereof.
- composition may comprise a derivative sequence having at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- composition may be for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual.
- IDS iduronate-2-sulfatase
- MPS II Mucopolysaccharidosis type II
- a polypeptide or nucleic acid for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptide comprises iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acid comprises an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- IDDS iduronate-2-sulfatase
- ApoEII Apolipoprotein E
- the polypeptide or nucleic acid may be tethered by means of a linker or a linker sequence.
- the tandem repeat of ApoEII may be upstream and/or downstream of the IDS.
- the IDS gene sequence may be a codon-optimised sequence of the wild-type IDS gene sequence.
- the IDS may comprise the amino acid sequence according to SEQ ID No. 5 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 5.
- the IDS gene sequence may comprise the sequence according to SEQ ID No. 1 or SEQ ID No. 2 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof.
- sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 1 or SEQ ID No. 2.
- the tandem repeat of the Apolipoprotein E may comprise the amino acid sequence according to SEQ ID No. 7 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence may comprise the amino acid sequence according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the linker may comprise the amino acid sequence according to SEQ ID No. 8 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- the linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- polypeptide or nucleic acid may be associated with or incorporated in a suitable peptide or nucleic acid delivery vehicle or vector.
- gene sequence is intended to cover nucleic acid sequences generally which are capable to being expressed into the requisite protein, including genomic sequences and sequences where one or more non-coding elements (such as introns) are not present including cDNA.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be for use in the treatment, management, retardation of progression or normalisation of development of a lysosomal storage disease.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be used in a method of treating, managing, retarding progression or normalising development of a lysosomal storage disease.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be used in a method of treating, managing, retarding progression or normalising development of a lysosomal storage disease, wherein the method comprises identifying a individual having said lysosomal storage disease and/or in need of elevated enzyme levels and administering a therapeutically effective amount of the composition, nucleic acid, vector or polypeptide to said individual.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a lysosomal storage disease.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be used in a method of treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be used in a method of treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency, wherein the method comprises identifying a individual having said iduronate-2-sulfatase (IDS) deficiency and/or in need of elevated iduronate-2-sulfatase (IDS) levels and administering a therapeutically effective amount of the composition, nucleic acid, vector or polypeptide to said individual.
- IDS iduronate-2-sulfatase
- compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells may be for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.
- IDS iduronate-2-sulfatase
- Diseases or conditions attributable to iduronate-2-sulfatase (IDS) deficiencies will include mucopolysaccharidosis type II (MPS II) or Hunters syndrome.
- compositions, nucleic acids, vectors and polypeptides may be a liquid or a solid, for example a powder, gel, or paste.
- a composition, nucleic acid, vectors, polypeptide and haematopoietic stem and progenitor cells (HSPCs) is a liquid, preferably an injectable liquid.
- injectable liquid will preferably be suitable for intravenous and intracranial administration.
- compositions, nucleic acids, vectors and polypeptides of the preceding aspects of the invention may yet further comprise a pharmaceutically acceptable excipient, adjuvant, diluent or carrier and provide a formulation.
- the formulation is sterile and pyrogen free.
- Suitable pharmaceutical carriers are well known in the art of pharmacy.
- the carrier(s) must be “acceptable” in the sense of being compatible with the agents of the invention and not deleterious to the recipients thereof.
- the carriers will be water or saline which will be sterile and pyrogen free; however, other acceptable carriers may be used.
- formulations of the invention(s) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- the formulations of the invention(s) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- the aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
- the preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- a method for delivering a deficient protein into the brain across the blood brain barrier in an individual suffering from a condition resulting from the deficiency in the protein comprising a viral vector comprising the gene sequence coding for the deficient protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, wherein the vector is transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to the individual where they express the deficient protein in levels sufficient which are sufficient to cross the blood brain barrier.
- HSPCs haematopoietic stem and progenitor cells
- the vector may comprise a sequence for an invariant flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- the deficient protein may comprise an enzyme.
- the enzyme may be a lysosomal storage disease enzyme.
- the enzyme comprises iduronate-2-sulfatase (IDS).
- the ApoEII tandem repeat gene sequence may comprise the sequence according to SEQ ID No. 3 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof
- the invariant flexible linker sequence may comprise the sequence according to SEQ ID No. 4 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof.
- compositions for use in the treatment of a lysosomal storage disease comprising a viral vector comprising the gene sequence coding for a deficient protein which is implicated in the lysosomal storage disease and which is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- ApoEII Apolipoprotein E
- the vector is preferably transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to an individual suffering from the lysosomal storage disease.
- HSPCs haematopoietic stem and progenitor cells
- the vector may comprise a sequence for an invariant flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- the deficient protein may comprise an enzyme.
- the enzyme may be a lysosomal storage disease enzyme.
- the enzyme comprises iduronate-2-sulfatase (IDS).
- the ApoEII tandem repeat gene sequence may comprise the sequence according to SEQ ID No. 3 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof, whereas the invariant flexible linker sequence may comprise the sequence according to SEQ ID No. 4 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof.
- a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence and one or more haematopoietic stem and progenitor cells (HSPCs), wherein the nucleic acid is capable of transducing the HSPCs.
- IDS iduronate-2-sulfatase
- ApoEII Apolipoprotein E
- HSPCs haematopoietic stem and progenitor cells
- the HSPCs will preferably be autologous, that is to say that they are derived from the individual to which the transduced HSPCs are to be administered.
- the HSPCs may be allogeneic, that is to say that they are derived from a different individual to which the transduced HSPCs are to be administered.
- the combination may comprise a nucleic acid as herein above described with respect to earlier aspects and may also be incorporated into a vector as also herein above described.
- a method of preparing a medicament for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency comprising:
- the vector comprises a lentiviral vector and the sequence coding for IDS is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence by means of a linker.
- ApoEII Apolipoprotein E
- HSPCs haematopoietic stem and progenitor cells
- the vector comprises a lentiviral vector and the sequence coding for the protein is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence by means of a linker.
- ApoEII Apolipoprotein E
- the present inventors have successfully show that by fusing the receptor-binding domain of human alipoprotein E (ApoE) as a tandem repeat to the IDS gene by means of an invariant flexible linker at the C-terminal in a 3 rd -generation lentiviral vector, they efficiently treat brain pathology and cognitive decline in MPS II.
- This allows HSPCs that are corrected ex vivo to express supra-physiological levels of IDS enzyme that may preferentially bypass the BBB in transplanted animals, thereby increasing the levels of enzyme that reach brain parenchyma from the bloodstream.
- FIG. 1 shows the generation and validation of a novel blood-brain barrier-crossing IDS enzyme in vitro.
- FIG. 2 shows that LV.IDS and LV.IDS.ApoEII improve brain-specific IDS activity and express supra-physiological levels of active IDS in peripheral organs.
- FIG. 3 shows LV.IDS.ApoEII correct cognitive abnormalities in MPS II mice, and all transplants ameliorate coordination and balance.
- (e) Graph showing 8-months-old control and treated mice were trialled 3 times on the accelerating rotarod for a maximum of 300 seconds (4-4rpm over 300 seconds);
- FIG. 4 shows LV.IDS.ApoEII normalises cytokines associated with neuro-inflammation in 8-months-old mice.
- (e) Graphs showing total relative amounts of total HS.
- compositional disaccharide analysis of HS from control and treated mice (n 6) analysed from brain samples.
- FIG. 5 shows WT-HSCT, LV.IDS and LV.IDS.ApoEII normalise gross skeletal abnormalities in MPS II mice.
- (a) X-ray images of control and treated MPS II mouse craniums at 8 months of age.
- (b) Graph showing Zygomatic arch widths
- (c) Graph showing humerus widths.
- FIG. 6 shows primary accumulation of heparan sulfate and its sulphation patterning in the brain is entirely normalized to WT levels using LV.IDS.ApoEII, not LV.IDS.
- A Total relative amounts of HS and
- B compositional disaccharide analysis of
- FIG. 7 shows LV.IDS.ApoEII normalizes astrogliosis in 8-months-old MPS II mice.
- A Representative images of 30 ⁇ m brains sections of the motor cortex (M2, approx. ⁇ 0.46 mm from bregma), caudate putamen (approx. ⁇ 0.46 mm from bregma), hippocampus (CA3) and amygdala (both approx.
- FIG. 8 shows a schematic diagram illustrating the proposed mechanism of action of the IDS.ApoEII enzyme in MPS II mice that allows IDS.ApoEII to correct the cognitive phenotype in MPS II mice.
- the ApoEII residue allows IDS to remain active for longer in plasma, leading to longer circulation time and higher chances of crossing into the CNS, whilst unmodified IDS is quickly degraded to an inactive form.
- FIG. 9 shows graphs and immunofluorescent staining images showing increased plasma stability and enhanced uptake by brain endothelial cells via multiple mechanisms.
- B Correlation between plasma IDS enzyme activity and IDS protein measured by ELISA.
- C FITC-dextran uptake into bEND.3 cells.
- D, E Immunofluorescent staining for LDLR (D) or LRP1 (E) in bEND.3 cells.
- Human IDS cDNA (SEQ ID No. 2) was adapted so as to form codon-optimised IDS cDNA (coIDS) (SEQ ID No. 1) and synthesised using GeneArt technology (ThermoFisher, Paisley, UK) and cloned into the third-generation LV pCCL.sin.cPPT.hCD11b.ccdB.wpre using Gateway cloning to create pCCL.sin.cPPT.hCD11b.IDS.wpre).
- An additional vector containing the cDNA sequence (SEQ ID No. 3) of the brain-targeting peptide sequence
- ApoEII as a tandem repeat (LRKLRKRLLLRKLRKRLL) (SEQ ID No. 7) was inserted downstream of the codon-optimised human IDS cDNA using the long invariant linker cDNA sequence (SEQ ID No. 4) so as to provide a LGGGGSGGGGSGGGGSGGGGS linker (SEQ ID No. 8) (32). Plasmids were codon-optimised and synthesised using GeneArt technology and cloned as previously described into a 3 rd -generation lentiviral backbone.
- the amino acid sequence for human IDS cDNA (SEQ ID No. 2) is referenced as SEQ ID No. 6, wherein the amino acid sequence for coIDS cDNA (SEQ ID No. 1) is referenced as SEQ ID No. 5.
- the resultant amino acid sequences for both human IDS cDNA and coIDS cDNA are the same.
- Human microglial cells (CHME3) were transfected with 2 ⁇ g of plasmid CD11b.IDS or CD11b.IDS.ApoEII DNA using 7.5 mM high-potency linear polyethylenimine (pH 7.4, MW 40,000, Polysciences Inc., Warrington, PA, USA) and 150 mM NaCl.
- Cells were collected 48 hours post-transfection in RIPA buffer (150 mM NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8) and incubated on a shaker at 4° C. for min, followed by centrifugation at 14,000 rpm, 4° C. for 20 minutes. Cell lysates were collected and stored at ⁇ 80° C. Media supernatants were collected 48 hours post-transfection and centrifuged at 1,000 rpm, 4° C. for 10 minutes to remove cell debris and stored at ⁇ 80° C.
- LV was produced (25) by transient transfection of HEK 293T cells with pMD2G, p ⁇ 8.91gag/pol, LV plasmid (24, 25, 34, 35) and 7.5 mM polyethylenimine (40 kDa,
- Lentiviral vector particles were concentrated by centrifugation at 21,191 g for 150 minutes at 4° C., resuspended in formulation buffer (PBS, 1 mg/ml human serum albumin, 5 ⁇ g/ml protamine sulphate, 40 mg/ml lactose, pH 7.2).
- formulation buffer PBS, 1 mg/ml human serum albumin, 5 ⁇ g/ml protamine sulphate, 40 mg/ml lactose, pH 7.2.
- EL4 mouse lymphoma cells ATCC TIB-39; ATCC, Manassas, VA, USA
- Genomic DNA was extracted using GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich, Poole, UK).
- the number of integrated viral genomes per cell was determined by quantitative PCR using a standard curve generated by dilutions of genomic DNA from an EL4 cell line clone containing 2 copies 2 integrated copies/cell of pHRsin.SFFV.eGFP.att.wpre (ALS EL4 eGFP 2.2) (24).
- a primer and probe set against wpre (TAMRA) were used as previously described (24, 25) and standardised against rodent gapdh (VIC) (Applied Biosystems, Paisley, UK).
- Total bone marrow mononuclear cells from MPSII mice were isolated from femurs and tibias, and lineage depleted using the murine lineage cell depletion kit (Miltenyi Biotec, Bisley, UK) according to the manufacturer's instructions.
- Cells were resuspended at 1 ⁇ 10 6 cells/ml in X-Vivo-10 media (BioWhittaker) containing 2% bovine serum albumin and stimulated using 100 ng/ml murine stem cell factor, 100 ng/ml murine fms-like tyrosine kinase-3 and 10 ng/ml recombinant murine interleukin-3 (Peprotech, Rocky Hill, NJ, USA) for 3 hours prior to transduction with a lentiviral vector for 20-24 hours at a multiplicity of infection of 100.
- X-Vivo-10 media BioWhittaker
- murine stem cell factor 100 ng/ml murine fms-like tyrosine kinase-3
- 10 ng/ml recombinant murine interleukin-3 (Peprotech, Rocky Hill, NJ, USA) for 3 hours prior to transduction with a lentiviral vector for 20-24 hours at a multiplicity of infection of 100.
- mice housed in individually ventilated cages were myeloablated using 125 mg/kg Busulfan (Busilvex; Pierre Fabre, Castres, France) in five daily doses (25 mg/kg/day) via intraperitoneal injection.
- Busulfan Busulfan
- WT-HSCT wild-type transplants
- Engraftment of donor haematopoietic stem cells was assessed at 4 weeks post-transplant in peripheral blood. Cells were stained with anti-mouse CD45.1-PE (donor
- HSCs HSCs
- CD45.2-FITC reactive HSCs
- CD3-Pe-Cy5 T-cell
- CD19-APC-Cy7 B-cell
- CD11b-Pe-Cy7 macrophage/microglia
- mice were anesthetized and transcardially perfused with 37° C. phosphate buffered saline to remove blood from organs.
- One brain hemisphere was fixed in 4% paraformaldehyde for 24 hours, transferred to a 30% sucrose, 2 mmol/l MgCl2/phosphate-buffered saline solution for 48 hours before freezing at ⁇ 80° C.
- Pieces of brain, spleen, heart, kidney, muscle and liver were snap-frozen on dry ice and stored at ⁇ 80° C.
- samples were homogenised and sonicated in homogenisation buffer (0.5 mol/l NaCl, 0.02 mol/l Tris, 0.1% Triton-X100, pH 7-7.5) before centrifugation at 14,000 rpm at 4° C. for 30 minutes.
- Bone marrow samples were collected by flushing one tibia and femur with 1 ml 2% FBS/PBS, filtered using a 70 ⁇ m filter and lysed using red blood cell lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2-7.4). Supernatant was collected and stored at ⁇ 80° C. Genomic DNA used for organ VCN analysis was extracted using GenElute Mammalian Genomic DNA Miniprep kit.
- IDS enzyme activity was measured in a two-step protocol using the fluorescent substrate MU-aldoA-2S (Carbosynth, Compton, UK) and laronidase (Aldurazyme, Genzyme) as the second step substrate as previously described (37).
- the amount of starting material was standardised to 20 ⁇ g of total protein for plasma, 40 ⁇ g for liver, spleen and bone marrow, and 60 ⁇ g for brain using a BCA assay (Thermo Fisher).
- Soluble brain fractions were collected and processed as previously described (38). Briefly, brain tissue was homogenised mechanically and Pronase-treated (1 mg/tissue) in 3 ml PBS for 4 hours at 37° C. 30 ⁇ l of TritonX100 was added to each sample for a 1% final concentration and incubated for an hour at room temperature prior to a second addition of 1 mg of Pronase for 4 hours at 37° C. Samples were loaded onto a pre-equilibrated DEAE-Sephacel column and hyaluronan was removed by washing the column with 50 ml of 0.25M NaCl/20 mM NaH 2 PO 4 H 2 O (pH 7). GAGs were eluted with 5 ml 1.5M NaCl/20 mM NaH 2 PO 4 H 2 O (pH 7), desalted using a PD10 column (Amersham, GE Healthcare) and freeze-fried.
- HS chains were digested using 5mIU each of heparinase I, II and III (Seikagaku, Tokyo, Japan) in 100 ⁇ l of 0.1M sodium acetate and 0.1M calcium acetate (pH 7).
- Resulting disaccharides were freeze-dried, re-dissolved in 20 ⁇ l of 0.1M 2-aminoacridone (AMAC) in 85% Me 2 SO/15% acetic acid (v/v) and incubated at room temperature for 20 minutes. 20 ⁇ l of NaBH 3 CN was added to each sample and incubated overnight at room temperature. AMAC-labelled disaccharides were separated by reverse phase high-performance liquid chromatography using a Zorbax Eclipse XDB-C18 column (2.1 ⁇ 500 mm, 3.5 ⁇ m) (Agilent Technologies, Stockport, UK).
- CBA Cytometric Bead Array
- CBA Cytometric Bead Array
- the rotarod test was used to evaluate motor coordination and balance at 32 weeks of age as previously described with minor modifications (41).
- Three test trials were carried out 24 hours post-training.
- the rotarod rotated at an accelerating speed of 4 to 40 rpm over 300 seconds, with a 5 minute rest between each trial. Latency to fall was recorded for all training and test trials, and latency to fall off was calculated as percentage of total trial time.
- mice were anesthetised using isoflurane and radiographed (45 keV) using the Bruker InVivo Xtreme system fitted with a high sensitivity, back-thinned back-illuminated 4MP, 16-bit, digital CCD camera. X-ray images were analysed using ImageJ software for individual bones widths.
- Novel lentiviral vectors encoding for human IDS alone, or human IDS linked to the human ApoE receptor-binding region as a tandem repeat, were constructed under the human myeloid-specific CD11b promoter (as illustrated in FIG. 1 a ).
- This sulphatase was modified by adding an invariant flexible linker to the C-terminal of the IDS gene, followed by the codon-optimised sequence of the receptor-binding portion of human ApoE as a tandem repeat (as illustrated in FIG. 1 b ).
- an invariant flexible linker to the C-terminal of the IDS gene, followed by the codon-optimised sequence of the receptor-binding portion of human ApoE as a tandem repeat (as illustrated in FIG. 1 b ).
- the addition of a linker and peptide can alter protein folding and detrimentally affect enzyme activity.
- a human microglial cell line (CHME3) was transfected with plasmid DNA expressing either LV.IDS or LV.IDS.ApoEII. 26-fold and 24-fold increases in cellular activity were observed with LV.IDS and LV.IDS.ApoEII, respectively (as shown in FIG. 1 c ). More importantly, increases of 84-fold and 81-fold in secreted IDS activity were detected 72 hours post-transfection ( FIG. 1 d ). Notably, this demonstrates that the C-terminal modifications do not negatively impact secretion or expression of the modified IDS enzyme in vitro.
- LV.IDS- and LV.IDS.ApoEII-Mediated Stem Cell Gene Therapy Improve IDS Enzyme Activity in the Brain and Express Supra-Physiological Levels of Active IDS in Peripheral Organs
- HSCs lineage-depleted haematopoietic stem cells
- IDS activity and vector copy number were measured in lineage-depleted HSCs (lin-HSCs) isolated from colony-forming unit (CFU) assays prior to transplant.
- the experiments demonstrated mean vector copy numbers of 3.1 and 3.8 in the LV.IDS- and LV.IDS.ApoEII-transduced HSCs (as shown in FIG. 2 b ) and overexpression of IDS enzyme by 124-fold and 152-fold over WT, respectively (as shown in FIG. 2 c ).
- These data demonstrate a positive correlation between the number of vector genome integrations and enzyme overexpression in haematopoietic cells.
- Flow cytometry analysis of peripheral WBCs at 4-weeks post-transplant demonstrated full engraftment of transduced cells into MPS II recipients, achieving between 80-100% of donor CD45.1+ cells (as shown in FIG. 2 d ).
- IDS enzyme activity levels in the brain were also elevated compared to untreated MPS II animals, and are equivalent to between 1.5% and 8% of normal IDS activity in WT brains.
- the WT-HSCT transplants restored IDS levels equivalent to WT in BM, plasma and spleen only, whilst no noticeable increase in IDS activity was detected in the brain over untreated MPS II animals.
- IDS activity in plasma of LV.IDS.ApoEII-treated animals was 3-fold higher than in the LV.IDS-treated group, suggesting potential alterations in enzyme stability and circulation time, secretion or uptake into cells (as shown in FIG. 2 f ).
- positive correlations between VCN and IDS enzyme activity levels further suggests that enzyme overexpression is driven by increases in genome integration of the IDS gene ( FIG. 2 g ).
- the dysfunction and uncontrolled accumulation of primary storage material in lysosomes in MPS II is likely to have a profound impact on lysosomal regulation and subsequent homeostasis.
- neurodegeneration is associated with lysosomal dysfunction and impaired autophagy.
- endogenous lysosomal enzymes can compensate for the deficiency of another lysosomal enzyme.
- Elevated levels of the lysosomal hydrolase 8-hexosaminidase were detected in the plasma (2-fold over WT), spleen (1.53-fold over WT) and brain (2-fold over WT) of untreated MPS II animals ( FIG. 2 N-P ).
- Plasma, spleen and brain levels of ⁇ -hexosaminidase were fully normalized back to WT levels in both LV.IDS- and LV.IDS.ApoEII-treated groups ( FIG. 2 N-P ).
- WT-HSCT normalized 8-hexosaminidase levels in plasma and spleen ( FIG. 2 N, 2 O ), and ameliorated levels in the brain without achieving complete normalization to WT levels ( FIG. 2 P ).
- HS and CS/DS glycosaminoglycans were purified from brain samples, and analysed and quantified by reverse-phase HPLC.
- a 6-fold increase in total HS was detected in brains of MPS II mice and mice treated with WT-HSCT ( FIG. 6 A ).
- Mice treated with LV.IDS showed a decrease in total HS accumulation in the brain to approximately 3-fold of WT levels.
- LV.IDS.ApoEII-treated mice showed a complete normalization of brain HS levels back to WT levels and significantly lower levels of HS when compared to LV.IDS ( FIG. 6 A ).
- HS composition analysis in MPS II mice showed that 31.1% of brain HS consisted of the fully sulfated UA(2S)-GIcNS(6S), compared to 12.3% in control WT mice ( FIG. 6 B ). In WT mice, these generally form clusters with other sulfated disaccharides along the chain, with significant increases in sulphation along the entirety of the HS chain in MPS II mice. This trend was reversed with WT-HSCT, LV.IDS and most effectively by LV.IDS.ApoEII. Similarly, increases in UA(2S)-GIcNS from 16.8% in WT mice to 31.1% in MPSII mice were observed, and fully corrected down to 18.4% in the LV.IDS.ApoEII group only.
- LV.IDS mediated improvements in the cerebral cortex, caudate putamen and amygdala, with engorged lysosomal compartments in the hippocampus still visible, suggesting only a partial correction of primary substrate accumulation, which strongly correlates to the levels of HS detected in the brain ( FIG. 6 A, 6 B ).
- LV.IDS.ApoEII fully normalised the increased LAMP2 staining in the cortex, caudate putamen and hippocampus, and considerably reduced the amount of lysosomal burden in the amygdala ( FIG. 6 C ).
- Astrocytes have been found to mediate a strong neuro-inflammatory response in MPS disorders, which translates into reactive gliosis, astrogliosis and increased levels of inflammatory cytokines.
- Brain coronal sections of control and treated MPS II mice were stained with the astrocytic marker GFAP (glial fibrillary associated protein; green) and LAMP2 (red).
- GFAP glial fibrillary associated protein
- LAMP2 red
- LV.IDS.ApoEII was able to fully abrogate astrogliosis and decrease LAMP2 staining back to WT levels in the cortex, caudate putamen, hippocampus and amygdala, correlating to decreases in substrate storage and inflammatory cytokines ( FIG. 6 A, 6 B, 6 A -D).
- LV.IDS decreased the number of reactive astrocytes present in the cortex, caudate putamen and amygdala.
- mice also underwent testing on the rotarod, a well-established test for sensorimotor coordination and balance in movement disorders in rodents (as shown in FIG. 3 d ). 8-months-old MPSII mice showed a reduction in performance on the accelerating rod as previously described. This was entirely rescued by all transplant treatments, including WT-HSCT (as shown in FIG. 3 e ).
- Cytometric bead arrays were used to quantify a number of inflammatory cytokines associated with chronic neuro-inflammation from whole brain extracts of control and treated mice at 8 months of age.
- CBA Cytometric bead arrays
- MIP-1 ⁇ , IL-1 ⁇ and RANTES protein levels were normalised with LV.IDS.ApoEII, and only partially with LV.IDS, and MCP-1 levels remained elevated for all groups (as shown in FIG. 4 b ).
- HS GAGs were purified from control and treated brains of MPS II mice and depolymerised into individual HS disaccharides using bacterial heparinase enzymes followed by fluorescent-tagging of reducing ends of individual disaccharides using AMAC.
- Reverse-phase HPLC separation was used to quantify and determine the individual contributions and sulphation patterns of each HS disaccharide.
- HPLC analysis allows for the relative levels of total HS to be calculated between WT, untreated MPS II and all treatment groups (as shown in FIG. 4 e ).
- a 6-fold increase in total HS was detected in brains of MPS II mice and mice treated with WT-HSCT (p ⁇ 0.0001).
- mice treated with LV.IDS showed a decrease in total HS accumulation in the brain to approximately 3-fold of WT levels.
- LV.IDS.ApoEII-treated mice showed a complete normalisation of brain HS levels back to WT levels (as shown in FIG. 4 e ).
- HS composition analysis showed significant increases of tri-sulphated disaccharide UA(2S)-GIcNS(6S), and increases in UA(2S)-GIcNS in untreated MPS II brains (as shown in FIG. 4 f ). This trend was partially reversed with WT-HSCT and LV.IDS, although full correction back to WT levels was only obtained in the LV.IDS.ApoEII group.
- Mono-sulphated HS disaccharides showed a significantly different trend; where untreated MPS II and WT-HSCT-treated levels of UA-GIcNS were lower than in WT brains (as shown in FIG. 4 f ). This was partially improved with the LV.IDS treatment, but only fully corrected in the LV.IDS.ApoEII group.
- the width of the zygomatic arches which are significantly increased in untreated MPS II animals, were reduced to WT dimensions in all transplanted groups, including WT-HSCT (as shown in FIGS. 5 a , 5 b ).
- Humerus widths were significantly reduced in WT-HSCT and LV.IDS groups, although full correction was only obtained in the LV.IDS.ApoEII-treated animals (as shown in FIG. 5 c ).
- femur widths in all treated animals showed no significant differences when compared to WT animals, suggesting significant skeletal rescue.
- Nppb and Myh7 two markers associated with cardiomyopathies and cardiac pathology, which could be indicators of higher risks of heart failure in the MPS II mouse model, were investigated.
- the expression of Nppb which encodes for the brain natriuretic peptide (BNP) that is secreted from the ventricles and regulates myocyte stretching and blood pressure, was found to be approximately 16-fold higher in MPS II than in WT male mice ( FIG. 5 H ).
- BNP brain natriuretic peptide
- Nppb expression was fully stabilized back to WT levels in WT-HSCT, LV.IDS and LV.IDS.ApoEII groups ( FIG. 5 H ).
- Myh7 expression primarily found in embryonic heart and encodes for myosin heavy chain beta as a key component of cardiac muscle and type I muscle fibers, was elevated in untreated MPS II animals.
- Myh7 expression in WT-HSCT, LV.IDS and LV.IDS.ApoEII groups was similar to WT expression ( FIG. 5 I ).
- the BBB endothelial cell line bEND.3 was used to determine whether there was any difference in enzyme uptake by endothelial cells. These cells produce an effective BBB layer in transwells ( FIG. 9 C ) and express both LDLR and LDLR-related protein 1 (LRP1) receptors ( FIG. 9 D, 9 E ). In order to ensure that each enzyme has a similar M6P status to that of the HSCGT produced enzyme, we used IDS and IDS.ApoEII enzyme secreted into the media after transfection of CHME3 human microglial cells and standardized by ELISA.
- IDS enzyme activity levels in plasma in the LV.IDS.ApoEII group were approximately 3-fold higher than in LV.IDS, even with lower VCN in WBCs. This translates to higher enzyme activity per copy in the LV.IDS.ApoEII group, suggesting that the ApoEII residue stabilizes or improves activity by changing its conformation, and appear to provide a protective effect against enzyme inactivation, but not clearance in plasma ( FIG. 8 ).
- a higher uptake of IDS.ApoEII in bEND.3 cells compared to unmodified IDS was detected and this was believed to be mediated predominantly by M6PR.
- the receptor-binding portion of apoE used in the IDS.ApoEII fusion enzyme (residues 142-147) is able to form a high affinity binding complex with an octasaccharide HS fragment composed of four repeats of UA(2S)-GIcNS(6S), which are abundant on endothelial cell surfaces and even more abundant in MPS II.
- HS typically acts as a co-receptor in many receptor ligand interactions and increased binding to HS proteoglycans (HSPG) through ApoEII could mediate an increase in cellular uptake through the LDLR, LDLR-related protein 1 (LRP1), M6P or by direct uptake of an apoE-HSPG complex.
- the receptor-binding portion of ApoE used here is able to form a high affinity binding complex with an octasaccharide HS fragment composed of four repeats of UA(2S)-GIcNS(6S), which are abundant on endothelial cell surfaces and even more abundant in MPS II.
- HS typically acts as a co-receptor in many receptor ligand interactions and increased binding to HS proteoglycans through ApoEII could mediate an increase in cellular uptake through the LDLR, LRP1, M6P or by direct uptake of an ApoE-HSPG complex.
- busulfan-conditioning leads to long-term increases in MCP-1 levels in the brain, a key mediator of cell transmigration to the CNS, and exerts a long-term trans-migratory effect.
- Approximately 20% of intravenously injected busulfan can cross the BBB, driving an even stronger pro-migratory MCP-1 response, which may ultimately facilitate the transmigration of donor-derived leukocytes across the BBB into the CNS in MPS II mice and provide additional means of trafficking enzyme into brain parenchyma.
- Microglial activation and astrocytosis are commonly reported in MPS disorders, including this study.
- complete normalisation of activated microglia was observed in the cortex and striatum of LV.IDS.ApoEII-treated mice, with only a 50% reduction in LV.IDS.
- LV.IDS.ApoEII treatment is comparable to the correction of astrogliosis and microglial activation reported using direct AAV9-IDS injection into the CSF (15).
- Peripheral inflammation was detected in livers of MPS II mice, with stark elevations in the levels of MCP-1, MIP-1 ⁇ and RANTES, and was abrogated by all transplants, indicating that peripheral IDS enzyme levels obtained with an allogeneic transplant can mediate a reduction in inflammation in the periphery.
- the Y-maze accounts for potential physical impairments in MPS II mice, unlike the Barnes maze, which may be invalidated by differential physical performance.
- Full behavioural correction of cognitive deficits was observed in the LV.IDS.ApoEII group alongside normalisation of coordination and balance.
- cognitive improvements likely stems from a combination of factors; a reduction in primary storage of HS alongside full abrogation of chronic neuro-inflammation, astrogliosis and microglial activation, all of which were only observed in LV.IDS.ApoEII-treated animals.
- the rescue of coordination and balance can be attributed to either central or peripheral rescue, or a combination thereof.
- the addition of the ApoE tandem peptide is absolutely necessary to target IDS enzyme to the brain to provide a full correction of the neurocognitive aspect in MPS II mice.
- the present inventors and others have reported progressive skeletal abnormalities in the MPS II mouse model, such as enlargement of craniofacial bone structures and femurs), correlating with the dysostosis multiplex seen in MPS II patients.
- ERT using idursulfase showed limited benefits in joint pain, stiffness, or range of motion, although earlier treatments could provide benefits.
- the widths of zygomatic arches, humerus and femurs were significantly reduced in all transplanted animals, including WT-HSCT, suggesting that some level of enzyme can penetrate bone tissue if treated at an early time point when skeletal phenotype remains mild. This is partly comparable to liver-directed AAV2/8TBG-IDS gene therapy, where craniofacial abnormalities were also corrected .
- HS GAGs also partly regulate Sonic Hedgehog (Shh), involved in heart ontogenesis and cardiac regeneration, which is downregulated alongside Ptch1, FoxM1 and Bmp4 in MPS II mice.
- Immunologically foreign proteins and enzymes such as ERT can trigger the release of inhibitory antibodies that may decrease therapeutic efficacy, although molecular and cellular chimerism after HSCT can induce tolerance to donor-specific antigens.
- IgG antibodies against human recombinant IDS in plasma of LV.IDS and LV.IDS.ApoEII-treated mice were not detected, and no adverse symptoms identified that could be attributed to neutralising antibodies. Overall, this is a strong indication that hematopoietic stem cell gene therapy (HSCGT) can induce tolerance and that both enzymes produced are well tolerated by the immune system.
- HCGT hematopoietic stem cell gene therapy
- ApoEII peptide residue does not generate increased immune sensitivity when compared to unmodified IDS.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptides comprise iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acids comprise an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence. The invention also relates to haematopoietic stem and progenitor cells (HSPCs) transduced by such nucleic acids for use in therapies.
Description
- This application is a divisional of U.S. application Ser. No. 16/484,311, filed Aug. 7, 2019, now U.S. Pat. No.: 11,701,390 B2 issued on Jul. 18, 2023 which is the U.S. National Stage of International Application No. PCT/GB2018/050347, filed on Feb. 7, 2018, published in English, which claims priority under 35 U.S.C. § 119 or 365 to Great Britain, Application No. 1701968.8, filed Feb. 7, 2017. The entire teachings of the above applications are incorporated herein by reference.
- This application incorporates by reference the Sequence Listing contained in the following eXtensible Markup Language (XML):
- File name: Sequence_Listings_FINAL_ST26.xml; created Dec. 16, 2022, 14,000 Bytes in size.
- The present invention relates to stem cell gene therapies for the treatment of mucopolysaccharidosis (MPS) II.
- Mucopolysaccharidosis type II (MPS II, OMIM #309900), or Hunter syndrome, is a paediatric X-linked lysosomal storage disorder caused by mutations in the IDS gene, leading to deficiencies in iduronate-2-sulfatase enzyme (EC 3.1.6.13). This IDS enzyme insufficiency, in turn, affects the catabolism of both heparan sulphate (HS) and dermatan sulphate, subsequently leading to their unregulated accumulation in the lysosomal compartment of all cells (1). MPS II affects 1.3 per 100,000 male live births (2-4) and has historically been classified as either attenuated or severe. Recently however, most clinical perspectives have described a continuum between two extremes, depending on the severity of symptoms (4). MPS II is a chronic and progressive multi-system disease affecting a multitude of organs such as the brain, heart, skeleton and joints. Clinical manifestations in the milder forms of MPS II include severe skeletal abnormalities, known as dysostosis multiplex, short stature, joint stiffness, and hepatosplenomegaly, accompanied by cardiorespiratory symptoms (4, 5). Severe MPS II additionally features progressive neurodegeneration, followed by death in teenage years due to obstructive airway disease and cardiac failure (4, 6, 7).
- Enzyme replacement therapy (ERT), where exogenous replacement enzyme is delivered intravenously and internalised by cells using the mannose-6-phosphate receptor, has been used to treat the somatic symptoms in MPS II patients regardless of disease severity (8, 9). However, enzyme circulating in the bloodstream is prevented from reaching the CNS by the blood-brain barrier (BBB), considerably reducing therapeutic benefits for the two-thirds of MPS II patients that are cognitively affected. Moreover, severe anaphylactic reactions to the replacement enzyme have been reported (9, 10), as well as neutralizing antibodies to the enzyme (11), which may decrease efficacy of the treatment (12).
- No current therapy has been specifically designed and approved to treat the neurological symptoms in MPS II, although a wide variety of strategies are in development. In particular, gene therapy is an attractive therapeutic possibility for a monogenic disorder such as MPS II. Stem cell gene therapy using second-generation lentiviral vectors (LV) (13) and direct injection of various adeno-associated vectors (AAV) into the CNS (5, 14, 15) have yielded promising results. However, scale up from the mouse brain to the human brain is the primary hurdle, as is adequate distribution of the therapeutic vector throughout brain tissue.
- Allogeneic stem cell transplantation, although recommended to treat neurological symptoms in MPS I Hurler (16-18), has been highly variable in treating the CNS in MPS II and is associated with high rates of morbidity and mortality primarily caused by rejection and graft-versus-host disease (19, 20). It has been suggested that the level of enzyme delivered from an allogeneic transplant, although sufficient to clear primary storage material in peripheral organs, may be too low in the brain and is therefore the limiting factor for complete neurological correction (21, 22). Indeed, supra-physiological enzyme levels in LV-transduced haematopoietic stem and progenitor cells (HSPCs) and their progeny have been shown to correct neurologic disease manifestations in metachromatic leukodystrophy, MPS I and MPS IIIA (21, 23-25). This leads to a reconstitution of the recipient's macrophage and microglia populations by cells derived from genetically-modified donor HSPCs, which synthesise and secrete lysosomal enzyme to cross-correct neighbouring cells (22). Moreover, corrected microglial cells that originate from myeloid progenitors may also significantly contribute to the turnover of CNS microglia, although controversy exists regarding their maintenance and renewal in adult CNS.
- The degree of efficacy of stem cell gene therapy approaches to treat the CNS seems to rely heavily on the level of enzyme produced and secreted from HSCs and their progeny (22, 23). High levels of enzyme are generally found in the bloodstream, but are prevented from entering the CNS by the dense microvasculature of the BBB (26).
- The primary hurdle in treating the neuropathology of diseases that involve the CNS is to bypass the BBB. One such strategy is to target proteins to translocate to the CNS via a process known as transcytosis, which exploits receptors located on the BBB surface, such as the transferrin receptor (TfR) and low-density lipoprotein receptor (LDLR) (27). The LDLR family are cell-surface receptors that bind alipoprotein (Apo) complexes and target them to the lysosomes (28). Apo complexes bind LDLR on the surface of the BBB and are transcytosed to the abluminal side before being released prior to uptake into neurons and astrocytes (29). A number of studies have exploited this minimally-invasive technology by fusing LDLR-binding domain peptides to enzymes of interest, and shown efficient delivery of these chimeric constructs across the BBB in animal models (29-33).
- We sought to harness this technology to efficiently treat brain pathology and cognitive decline in MPS II by fusing the receptor-binding domain of human alipoprotein E (ApoE) as a tandem repeat to the IDS gene by means of an invariant flexible linker at the C-terminal in a 3rd-generation lentiviral vector. This allows HSPCs that are corrected ex vivo to express supra-physiological levels of IDS enzyme that may preferentially bypass the BBB in transplanted animals, thereby increasing the levels of enzyme that reach brain parenchyma from the bloodstream.
- It is an object of the present invention to overcome one or more of the problems associated with the above proposed therapies for MPSII. It is also an object of the present invention to provide an effective treatment for MPSII. Such a treatment would ideally be relatively easy to administer and have a low toxicological profile. It would also be desirable if such a treatment was able to overcome or obviate issues concerned with administering treatments which need to cross the blood brain barrier.
- In accordance with an aspect of the present invention, there is provided a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence, or a repeat of part of the ApoEII gene sequence.
- The nucleic acid may further comprise an intervening linker sequence located between the IDS sequence and the ApoEII sequence.
- The IDS sequence may be a codon-optimised sequence of the wild-type IDS sequence.
- The repeat of the ApoEII sequence may be in the form of a tandem repeat. The repeat of the ApoEII sequence may be upstream and/or downstream of the IDS sequence.
- The IDS sequence may comprise the sequence according to SEQ ID No. 1 or SEQ ID No. 2 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 1 or SEQ ID No. 2.
- The ApoEII sequence may comprise one or more sequences according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The intervening linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- In accordance with another aspect of the present invention, there is provided a nucleic acid for use in increasing the plasma level, or stability in plasma, of an enzyme in an individual, the nucleic acid comprising an enzyme gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence.
- The nucleic acid may further comprise an intervening linker sequence located between the enzyme sequence and the ApoEII sequence.
- The enzyme sequence may be a codon-optimised sequence of the enzyme sequence.
- The repeat of the ApoEII sequence may be in the form of a tandem repeat. The repeat of the ApoEII sequence may be upstream and/or downstream of the enzyme sequence.
- The ApoEII sequence may comprise one or more sequences according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The intervening linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The enzyme may be one which is deficient or present at low plasma levels in individuals suffering from lysosomal storage disease. The lysosomal storage disease may comprise Mucopolysaccharidosis type II (MPS II).
- The nucleic acid may be a DNA, RNA, cDNA, or PNA and may be recombinant or synthetic. It may be single stranded or double stranded. The nucleic acid sequence may be derived by cloning, for example using standard molecular cloning techniques including restriction digestion, ligation, gel electrophoresis (for example as described in Sambrook et al; Molecular Cloning: A laboratory manual, Cold Spring Harbour laboratory Press). The nucleic acid sequence may be isolated or amplified using PCR technology. Such technology may employ primers based upon the sequence of the nucleic acid sequence to be amplified. With the sequence information provided, the skilled person can use available cloning techniques to produce a nucleic acid sequence or vector suitable for transduction into a cell.
- The codon optimised IDS nucleic acid sequence may be optimised in a number of ways so as to enable enhanced expression or activity. For example the sequence may have been optimised by selecting codons most common in human cells and/or reducing one or more secondary structures and hairpins which may arise in subsequently formed mRNA and/or inserting a Kozak sequence at the ATG start site.
- Preferably, the nucleic acid sequence is provided with, in or as part of an expression vector. Preferably, it may be provided as a gene therapy vector, preferably which is suitable for ex vivo transduction in haematopoietic stem and progenitor cells (HSPCs) which are subsequently returned to a mammalian body for expression. The vector may be viral or non-viral (e.g. a plasmid). Viral vectors include those derived from lentivirus, adenovirus, adenoassociated virus (AAV) including mutated forms, retrovirus, herpes virus, vaccinia virus, MMLV, GaLV, Simian Immune Deficiency Virus (SIV), HIV, pox virus, and SV40. A viral vector is preferably replication defective, although it is envisaged that it may be replication deficient, replication competent or conditional. A viral vector may typically persist in an extrachromosomal state without integrating into the genome of the target neural cells. A preferred viral vector is a lentivirus vector. The viral vector may be modified to delete any non-essential sequences and these will be apparent to the skilled addressee.
- The viral vector has the ability to enter a cell. However, a non-viral vector such as a plasmid may be complexed with an agent to facilitate its uptake by a target cell. Such agents include polycationic agents. Alternatively, a delivery system such as a liposome based delivery system may be used.
- The vector for use in the present invention is preferably suitable for use in or ex vivo or in vitro, and is preferably suitable for use in a human. Most preferably, the vector is suitable for transducing haematopoietic stem and progenitor cells (HSPCs) ex vivo.
- The vector will preferably comprise one or more regulatory sequences to direct expression of the nucleic acid. A regulatory sequence may include a promoter operably linked to the IDS and ApoEII nucleic acid sequence, an enhancer, a transcription termination signal, a polyadenylyation sequence, an origin of replication, a nucleic acid restriction site, and a homologous recombination site. A vector may also include a selectable marker, for example to determine expression of the vector in a growth system (for example a bacterial cell) or in a target cell.
- By “operably linked” means that the nucleic acid sequence is functionally associated with the sequence to which it is operably linked, such that they are linked in a manner such that they affect the expression or function of one another. For example, a nucleic acid sequence operably linked to a promoter will have an expression pattern influenced by the promoter.
- In accordance with an aspect of the present invention, there is provided haematopoietic stem and progenitor cells (HSPCs) for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs are removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs are administered to the individual.
- In accordance with a related aspect of the present invention, there is provided haematopoietic stem and progenitor cells (HSPCs) for use in a method of, or for the, treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs administered to the individual.
- In accordance with a related aspect of the present invention, there is provided haematopoietic stem and progenitor cells (HSPCs) for use in a method of treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the method comprises identifying an individual having said iduronate-2-sulfatase (IDS) deficiency and/or in need of elevated iduronate-2-sulfatase (IDS) levels, removing a portion of HSPCs from the individual, transduced the HSPCs ex vivo with the nucleic acid as herein above described and administering a therapeutically effective amount of the transduced HSPCs to the individual.
- In accordance with a related invention, there is provided haematopoietic stem and progenitor cells (HSPCs) for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid as herein above described, and the transduced HSPCs formed into a medicament for administration to the patient.
- Whilst the above HSPCs aspects are preferably utilising autologous HSPCs (where they have first been removed from the patient or individual), allogeneic HSPCs may also be utilised, therefore removing the need that the HSPCs be removed from the patient or individual, transduced ex vivo and then administered to the patient or individual.
- Allogeneic HSPCs may be derived from cord blood.
- In accordance with an aspect of the present invention, there is provided a composition comprising:
- a) a first moiety comprising iduronate-2-sulfatase (IDS); and
- b) a second moiety comprising a repeat of Apolipoprotein E (ApoEII).
- The repeat of ApoEII may be in the form of a tandem repeat. The second moiety may be upstream and/or downstream of the first moiety.
- The first and second moiety may have an intervening linker moiety located there between.
- The amino acid sequence of the first moiety may comprise the sequence according to SEQ ID No. 5 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 5.
- The amino acid sequence of the second moiety may comprise one or more sequences according to SEQ ID No. 7 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The amino acid sequence of the intervening linker moiety may comprise the sequence according to SEQ ID No. 8 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- In accordance with a further aspect of the present invention, there is provided a composition for increasing the plasma level, or stability in plasma, of an enzyme comprising:
- a) a first moiety comprising the enzyme; and
- b) a second moiety comprising a repeat of Apolipoprotein E (ApoEII).
- The repeat of ApoEII may be in the form of a tandem repeat. The second moiety may be upstream and/or downstream of the first moiety.
- The first and second moiety may have an intervening linker moiety located there between.
- Advantageously, the inventors have found that they are able to increase the activity in plasma of enzymes, suggesting potential alterations in enzyme stability and circulation time, secretion or uptake into cells by including a tandem repeat of ApoEII via a linker to the enzyme.
- In a further aspect of the present invention, there is provided a composition comprising a nucleic acid according to SEQ ID No. 1 or a derivative sequence having at least 95% homology thereof.
- The composition may comprise a derivative sequence having at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The composition may be for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual.
- In another aspect of the present invention, there is provided a polypeptide or nucleic acid for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the polypeptide comprises iduronate-2-sulfatase (IDS) tethered to a tandem repeat of Apolipoprotein E (ApoEII) or the nucleic acid comprises an iduronate-2-sulfatase (IDS) gene sequence tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- The polypeptide or nucleic acid may be tethered by means of a linker or a linker sequence.
- The tandem repeat of ApoEII may be upstream and/or downstream of the IDS.
- The IDS gene sequence may be a codon-optimised sequence of the wild-type IDS gene sequence.
- The IDS may comprise the amino acid sequence according to SEQ ID No. 5 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof. Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 5.
- The IDS gene sequence may comprise the sequence according to SEQ ID No. 1 or SEQ ID No. 2 or a derivative sequence having at least 90% homology thereof. Where the sequence is a derivative sequence, preferably it has at least 93% homology thereof.
- Even more preferred, the sequence may be a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology with SEQ ID No. 1 or SEQ ID No. 2.
- The tandem repeat of the Apolipoprotein E (ApoEII) may comprise the amino acid sequence according to SEQ ID No. 7 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof. The tandem repeat of the Apolipoprotein E (ApoEII) gene sequence may comprise the amino acid sequence according to SEQ ID No. 3 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The linker may comprise the amino acid sequence according to SEQ ID No. 8 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The linker sequence may comprise the sequence according to SEQ ID No. 4 or a derivative sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology thereof.
- The polypeptide or nucleic acid may be associated with or incorporated in a suitable peptide or nucleic acid delivery vehicle or vector.
- The term ‘gene sequence’ is intended to cover nucleic acid sequences generally which are capable to being expressed into the requisite protein, including genomic sequences and sequences where one or more non-coding elements (such as introns) are not present including cDNA.
- In all above aspects, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be for use in the treatment, management, retardation of progression or normalisation of development of a lysosomal storage disease. Alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be used in a method of treating, managing, retarding progression or normalising development of a lysosomal storage disease. Alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be used in a method of treating, managing, retarding progression or normalising development of a lysosomal storage disease, wherein the method comprises identifying a individual having said lysosomal storage disease and/or in need of elevated enzyme levels and administering a therapeutically effective amount of the composition, nucleic acid, vector or polypeptide to said individual. Yet further alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a lysosomal storage disease.
- In particular, in all above aspects, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency. Alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be used in a method of treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency. Alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be used in a method of treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency, wherein the method comprises identifying a individual having said iduronate-2-sulfatase (IDS) deficiency and/or in need of elevated iduronate-2-sulfatase (IDS) levels and administering a therapeutically effective amount of the composition, nucleic acid, vector or polypeptide to said individual. Yet further alternatively or additionally, the compositions, nucleic acids, vectors, polypeptides and haematopoietic stem and progenitor cells (HSPCs) may be for use in the manufacture of a medicament for treating, managing, retarding progression or normalising development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency. Diseases or conditions attributable to iduronate-2-sulfatase (IDS) deficiencies will include mucopolysaccharidosis type II (MPS II) or Hunters syndrome.
- The compositions, nucleic acids, vectors and polypeptides may be a liquid or a solid, for example a powder, gel, or paste. Preferably, a composition, nucleic acid, vectors, polypeptide and haematopoietic stem and progenitor cells (HSPCs) is a liquid, preferably an injectable liquid. Such an injectable liquid will preferably be suitable for intravenous and intracranial administration.
- The compositions, nucleic acids, vectors and polypeptides of the preceding aspects of the invention may yet further comprise a pharmaceutically acceptable excipient, adjuvant, diluent or carrier and provide a formulation.
- By “pharmaceutically acceptable” is included that the formulation is sterile and pyrogen free. Suitable pharmaceutical carriers are well known in the art of pharmacy. The carrier(s) must be “acceptable” in the sense of being compatible with the agents of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free; however, other acceptable carriers may be used.
- In human therapy, formulations of the invention(s) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- The formulations of the invention(s) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- In accordance with another aspect of the present invention, there is provided a method for delivering a deficient protein into the brain across the blood brain barrier in an individual suffering from a condition resulting from the deficiency in the protein, the composition comprising a viral vector comprising the gene sequence coding for the deficient protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, wherein the vector is transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to the individual where they express the deficient protein in levels sufficient which are sufficient to cross the blood brain barrier.
- The vector may comprise a sequence for an invariant flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- The deficient protein may comprise an enzyme. The enzyme may be a lysosomal storage disease enzyme. Preferably, the enzyme comprises iduronate-2-sulfatase (IDS).
- In the method, the ApoEII tandem repeat gene sequence may comprise the sequence according to SEQ ID No. 3 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof, whereas the invariant flexible linker sequence may comprise the sequence according to SEQ ID No. 4 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof.
- In accordance with yet another aspect of the present invention, there is provided a composition for use in the treatment of a lysosomal storage disease, wherein the composition comprises a viral vector comprising the gene sequence coding for a deficient protein which is implicated in the lysosomal storage disease and which is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- The vector is preferably transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to an individual suffering from the lysosomal storage disease.
- The vector may comprise a sequence for an invariant flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence.
- The deficient protein may comprise an enzyme. The enzyme may be a lysosomal storage disease enzyme. Preferably, the enzyme comprises iduronate-2-sulfatase (IDS).
- The ApoEII tandem repeat gene sequence may comprise the sequence according to SEQ ID No. 3 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof, whereas the invariant flexible linker sequence may comprise the sequence according to SEQ ID No. 4 or variant sequences having up to 95%, up to 96%, up to 97%, up to 98% or up to 99% homology thereof.
- In accordance with another aspect of the present invention, there is provided a combination of a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence and one or more haematopoietic stem and progenitor cells (HSPCs), wherein the nucleic acid is capable of transducing the HSPCs.
- The HSPCs will preferably be autologous, that is to say that they are derived from the individual to which the transduced HSPCs are to be administered. Alternatively, the HSPCs may be allogeneic, that is to say that they are derived from a different individual to which the transduced HSPCs are to be administered.
- The combination may comprise a nucleic acid as herein above described with respect to earlier aspects and may also be incorporated into a vector as also herein above described.
- In another aspect, there is provided a method of preparing a medicament for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency, the method comprising:
- (a) providing one or more HSPCs;
- (b) providing a viral vector comprising a sequence coding for IDS tethered to a tandem repeat of the Apolipoprotein E (ApoEII) sequence; and
- (c) combining the HSPCs and viral vector under conditions effective enable transduction of the HSPCs with the gene sequence, wherein the transduced HSPCs express IDS.
- Preferably, the vector comprises a lentiviral vector and the sequence coding for IDS is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence by means of a linker.
- In a further aspect, there is provided a method of expressing a deficient protein and/or higher levels of a protein in haematopoietic stem and progenitor cells (HSPCs), the method comprising:
- (a) providing one or more HSPCs;
- (b) providing a viral vector comprising the sequence coding for the protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) sequence; and
- (c) combining the HSPCs and viral vector under conditions effective to enable transduction of the HSPCs with the sequence.
- Preferably, the vector comprises a lentiviral vector and the sequence coding for the protein is tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence by means of a linker.
- Surprisingly, and advantageously, the present inventors have successfully show that by fusing the receptor-binding domain of human alipoprotein E (ApoE) as a tandem repeat to the IDS gene by means of an invariant flexible linker at the C-terminal in a 3rd-generation lentiviral vector, they efficiently treat brain pathology and cognitive decline in MPS II. This allows HSPCs that are corrected ex vivo to express supra-physiological levels of IDS enzyme that may preferentially bypass the BBB in transplanted animals, thereby increasing the levels of enzyme that reach brain parenchyma from the bloodstream.
- Herein reference to “a” or “an” includes within its scope both the singular, and the plural, i.e. one or more.
- Unless stated otherwise, the features of each aspect applies to the other aspects of the invention, mutatis mutandis.
- Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
- Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and figures), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
- Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
-
FIG. 1 shows the generation and validation of a novel blood-brain barrier-crossing IDS enzyme in vitro. (a) Schematic representation showing pCCL lentiviral vectors encoding for the codon-optimised human IDS gene, or the human IDS gene followed by a flexible linker and the ApoEII peptide sequence as a tandem repeat. Both lentiviral vectors are driven by the human CD11b promoter. (b) Schematic representation and sequences of the invariant linker and ApoEII tandem repeat added at the C-terminal of the IDS gene. (c) Graphs showing intracellular IDS enzyme activity measured in a human microglial cell line (CHME3) after transfection with 2 μg plasmid DNA of either LV.IDS or LV.IDS.ApoEII for 24 hours, and measured 48 hours post-transfection. n=3. (d) Secreted IDS enzyme activity measured in transfected human microglial cells (CHME3) with 2 μg plasmid DNA of either LV.IDS or LV.IDS.ApoEII for 24 hours, and measured 48 hours post-transfection. n=3one-way ANOVA, **=p<0.01 vs. non-transfected. (E) Uptake of IDS or IDS.ApoEII from media into bEND.3 cells after 24 hours, n=3 wells/condition (F) Receptor-mediated uptake of IDS or IDS.ApoEII through M6PR or LDLR 24 hours after blocking with 7.5 mM M6P or 50 μg/ml human recombinant apoE for 4 hours, n=3 wells/condition. Data are shown as mean±SEM, two-way ANOVA, *=p<0.05, **=p<0.01, ****=p<0.0001 comparisons are indicated by brackets; -
FIG. 2 shows that LV.IDS and LV.IDS.ApoEII improve brain-specific IDS activity and express supra-physiological levels of active IDS in peripheral organs. (a) Schematic representation of the stem cell gene therapy strategy. Busulfan-conditioned 6-8-week-old MPS II mice were transplanted with 4×105 lin-HSCs transduced with LV.IDS or LV.IDS.ApoEII at an MOI of 100, or 1×107 total bone marrow cells. (b) Graph showing vector copy number and (c) Graph showing IDS enzyme activity were measured in transduced HSCs from colony-forming unit assays at transplant. (d) Graph showing donor chimerism in WBCs was measured by flow cytometry at 4-weeks post-transplant in all transplanted mice. (e) Graph showing vector copy number and (f) Graph showing IDS enzyme activity were measured in organs taken at 8 months of age, including BM, WBC/plasma, spleen and brain, from control and treated mice (n=6). (I) Graph showing IDS enzyme activity were measured in heart from control taken at 8 months of age. (g) Graph showing VCN to enzyme activity correlation in individual mice in bone marrow, WBC/plasma, spleen and brain (n=6) (M) Correlation between plasma IDS enzyme activity and IDS protein measured by ELISA. Levels of lysosomal enzyme β-hexosaminidase activity were analysed in the (N) plasma, (O) spleen and (P) brain of 8-months old mice. Data are shown as mean ±SEM, one way- ANOVA, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs. MPSII, other comparisons are indicated by brackets; -
FIG. 3 shows LV.IDS.ApoEII correct cognitive abnormalities in MPS II mice, and all transplants ameliorate coordination and balance. (a) Schematic representation of the Y-maze test. Mice are placed in the centre and allowed to explore freely for 10 minutes. (b) Graph showing spontaneous alternation in the Y-maze was measured in control and treated mice at 8 months of age, and (c) Graph showing the total number of entries was recorded as a proxy measure of locomotor activity. (d) Representation of the accelerating rotarod. (e) Graph showing 8-months-old control and treated mice were trialled 3 times on the accelerating rotarod for a maximum of 300 seconds (4-4rpm over 300 seconds); -
FIG. 4 shows LV.IDS.ApoEII normalises cytokines associated with neuro-inflammation in 8-months-old mice. (a)-(c) Graphs showing cytokine bead arrays measuring MIP-1α, MCP-1, IL-1α and RANTES were performed on whole brain lysate of 8-months-old mice using flow cytometry (n=6). (e) Graphs showing total relative amounts of total HS. (f) compositional disaccharide analysis of HS from control and treated mice (n=6) analysed from brain samples. (g) Representative images of 30 μm sections of the motor cortex (M2) and striatum stained with isolectin B4 (ILB4) to identify activated microglia, 40×. Four 30 μm sections per mouse of the (h) cortex and (i) striatum were counted for the number of ILB4-positive cells (from approx. 0.26 mm to −1.94 mm from bregma), n=3/group. Scale bar: 50 μm. Data are shown as mean±SEM, one-way ANOVA, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.001 vs. MPSII, other comparisons are indicated by brackets; -
FIG. 5 shows WT-HSCT, LV.IDS and LV.IDS.ApoEII normalise gross skeletal abnormalities in MPS II mice. (a) X-ray images of control and treated MPS II mouse craniums at 8 months of age. (b) Graph showing Zygomatic arch widths (c) Graph showing humerus widths. (d) Graph showing femur widths were analysed using ImageJ software (n=5-11); Cytokine bead arrays measuring (E) MCP-1, (F) MIP-1α and (G) RANTES and were performed on liver lysates of 8-months-old mice using flow cytometry, n=4-6. Gene expression of (H) Nppb and (I) Myh7 in hearts of control and treated MPS II animals (WT n=3, MPS II n=4, WT-HSCT, LV.IDS and LV.IDS.ApoEII n=6). (J) IDS-specific IgG antibody titers were measured in plasma. (K) Total IgG antibodies against IDS were determined in plasma samples by ELISA (Pos. control n=1, neg. control n=6, LV.IDS/LV.IDS.ApoEII n=6). Data are shown as mean±SEM, one-way ANOVA, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs. MPSII; -
FIG. 6 shows primary accumulation of heparan sulfate and its sulphation patterning in the brain is entirely normalized to WT levels using LV.IDS.ApoEII, not LV.IDS. (A) Total relative amounts of HS and (B) compositional disaccharide analysis of - HS from control and treated mice were analysed from brain samples, n=6/group. (C) Representative images of 30 μm brains sections of the motor cortex (M2), caudate putamen (both approx. −0.46 mm from bregma), hippocampus (CA3) and amygdala (both approx. −1.22 mm from bregma) from control and treated mice stained with NeuN (neuronal nuclei; green) and LAMP2 (lysosomal compartment; red), n=6/group, nonlinear adjustments were made equally in all images to reduce background; gamma 0.72, input levels 0-190. Scale bar: 50 μm. Data are shown as mean ±SEM, one-way ANOVA, *=p<0.05, **=p<0.01,***=p<0.001, ****=p<0.0001 vs. MPSII, other comparisons are indicated by brackets;
-
FIG. 7 shows LV.IDS.ApoEII normalizes astrogliosis in 8-months-old MPS II mice. (A) Representative images of 30 μm brains sections of the motor cortex (M2, approx. −0.46 mm from bregma), caudate putamen (approx. −0.46 mm from bregma), hippocampus (CA3) and amygdala (both approx. −1.22 mm from bregma) from control and treated mice stained with GFAP (glial fibrillary acidic protein; green) and LAMP2 (lysosomal compartment; red), n=6/group, 40×, nonlinear adjustments were made equally in all images to reduce background; gamma 0.72, input levels 0-190. Scale bar: GFAP immunofluorescence was quantified in the (B) cortex and (C) amygdala of 8-months-old MPS II mice, n=3/group, AU: arbitrary units. Data are shown as mean±SEM, one-way ANOVA, *=p<0.05, **=p<0.01 vs. MPSII, other comparisons are indicated by brackets; -
FIG. 8 shows a schematic diagram illustrating the proposed mechanism of action of the IDS.ApoEII enzyme in MPS II mice that allows IDS.ApoEII to correct the cognitive phenotype in MPS II mice. The ApoEII residue allows IDS to remain active for longer in plasma, leading to longer circulation time and higher chances of crossing into the CNS, whilst unmodified IDS is quickly degraded to an inactive form. Within the brain, corrected microglia derived from the bone marrow secrete IDS or IDS.ApoEII in similar levels but IDS.ApoEII uptake is more efficient and couple with improved stability, leads to better correction of primary storage and neuro-inflammation; and -
FIG. 9 shows graphs and immunofluorescent staining images showing increased plasma stability and enhanced uptake by brain endothelial cells via multiple mechanisms. (A) Plasma clearance of IDS protein measured in MPS II mice injected with 12 ng of total IDS enzyme at 1, 10 and 30 minutes post-injection, n=2/group. (B) Correlation between plasma IDS enzyme activity and IDS protein measured by ELISA. (C) FITC-dextran uptake into bEND.3 cells. (D, E) Immunofluorescent staining for LDLR (D) or LRP1 (E) in bEND.3 cells. (F) Uptake of IDS or IDS.ApoEII produced by CHME3 cells added to growth media of bEND.3 cells grown in monolayer culture for 24 hours. n=2 independent experiments, with 3 wells/condition. (G) Uptake of IDS or IDS.ApoEII produced by CHME3 cells added to growth media of bEND.3 cells grown in transwell culture for 24 hours. n=3 independent experiments, with 2 wells/condition. (H) Percentage transcytosis to the basal layer of bEND.3 cells from G. (I) Receptor-mediated uptake of IDS or IDS.ApoEII after 24 hours, following heparinase treatment of the cell layer or blocking with 7.5mM M6P or human recombinant ApoE for 1 hour prior to enzyme addition. n=3 wells/condition. Data are mean ±SEM, one-way ANOVA or T-test as appropriate, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 vs. MPS II. - Experiments were conducted to transduce a vector containing a codon optimised IDS with haematopoietic stem and progenitor cells (HSPCs) which were subsequently tested in a mouse model for the expression of IDS and in particular to assess the amount of IDS passing through the blood brain barrier.
- Human IDS cDNA (SEQ ID No. 2) was adapted so as to form codon-optimised IDS cDNA (coIDS) (SEQ ID No. 1) and synthesised using GeneArt technology (ThermoFisher, Paisley, UK) and cloned into the third-generation LV pCCL.sin.cPPT.hCD11b.ccdB.wpre using Gateway cloning to create pCCL.sin.cPPT.hCD11b.IDS.wpre). An additional vector containing the cDNA sequence (SEQ ID No. 3) of the brain-targeting peptide sequence
- ApoEII as a tandem repeat (LRKLRKRLLLRKLRKRLL) (SEQ ID No. 7) was inserted downstream of the codon-optimised human IDS cDNA using the long invariant linker cDNA sequence (SEQ ID No. 4) so as to provide a LGGGGSGGGGSGGGGSGGGGS linker (SEQ ID No. 8) (32). Plasmids were codon-optimised and synthesised using GeneArt technology and cloned as previously described into a 3rd-generation lentiviral backbone. The amino acid sequence for human IDS cDNA (SEQ ID No. 2) is referenced as SEQ ID No. 6, wherein the amino acid sequence for coIDS cDNA (SEQ ID No. 1) is referenced as SEQ ID No. 5. The resultant amino acid sequences for both human IDS cDNA and coIDS cDNA are the same.
- Human microglial cells (CHME3) were transfected with 2 μg of plasmid CD11b.IDS or CD11b.IDS.ApoEII DNA using 7.5 mM high-potency linear polyethylenimine (pH 7.4, MW 40,000, Polysciences Inc., Warrington, PA, USA) and 150 mM NaCl. Cells were collected 48 hours post-transfection in RIPA buffer (150 mM NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8) and incubated on a shaker at 4° C. for min, followed by centrifugation at 14,000 rpm, 4° C. for 20 minutes. Cell lysates were collected and stored at −80° C. Media supernatants were collected 48 hours post-transfection and centrifuged at 1,000 rpm, 4° C. for 10 minutes to remove cell debris and stored at −80° C.
- LV was produced (25) by transient transfection of HEK 293T cells with pMD2G, pΔ8.91gag/pol, LV plasmid (24, 25, 34, 35) and 7.5 mM polyethylenimine (40 kDa,
- Polysciences, Warrington, PA, USA) (36). Lentiviral vector particles were concentrated by centrifugation at 21,191 g for 150 minutes at 4° C., resuspended in formulation buffer (PBS, 1 mg/ml human serum albumin, 5 μg/ml protamine sulphate, 40 mg/ml lactose, pH 7.2). EL4 mouse lymphoma cells (ATCC TIB-39; ATCC, Manassas, VA, USA) were transduced with three dilutions of concentrated LV and collected 72 hours later. Genomic DNA was extracted using GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich, Poole, UK). The number of integrated viral genomes per cell was determined by quantitative PCR using a standard curve generated by dilutions of genomic DNA from an EL4 cell line clone containing 2
copies 2 integrated copies/cell of pHRsin.SFFV.eGFP.att.wpre (ALS EL4 eGFP 2.2) (24). A primer and probe set against wpre (TAMRA) were used as previously described (24, 25) and standardised against rodent gapdh (VIC) (Applied Biosystems, Paisley, UK). - Female heterozygous for the X-linked allele were obtained from Prof. Joseph Muenzer (University of North Carolina at Chapel Hill, NC, USA) and bred with wild-type C57BL/6J males (Envigo, Alconbury, UK) to obtain wild-type males and females, and affected hemizygous males and carrier females. MPSII were backcrossed onto the PEP3 CD45.1 congenic background (B6.SJL-PtprcaPepcb/BoyJ) to distinguish donor and recipient cells as previously described (24). WT littermates were used as controls throughout.
- Total bone marrow mononuclear cells from MPSII mice were isolated from femurs and tibias, and lineage depleted using the murine lineage cell depletion kit (Miltenyi Biotec, Bisley, UK) according to the manufacturer's instructions. Cells were resuspended at 1×106 cells/ml in X-Vivo-10 media (BioWhittaker) containing 2% bovine serum albumin and stimulated using 100 ng/ml murine stem cell factor, 100 ng/ml murine fms-like tyrosine kinase-3 and 10 ng/ml recombinant murine interleukin-3 (Peprotech, Rocky Hill, NJ, USA) for 3 hours prior to transduction with a lentiviral vector for 20-24 hours at a multiplicity of infection of 100.
- Six-to-eight-week-old mice housed in individually ventilated cages were myeloablated using 125 mg/kg Busulfan (Busilvex; Pierre Fabre, Castres, France) in five daily doses (25 mg/kg/day) via intraperitoneal injection. Prior to myeloablation, mice received acidified water (pH 2.8), irradiated food and mash. Within 24 hours of receiving the last injection of busulfan, mice were injected with 3-4×105 lineage-depleted transduced haematopoietic stem cells through the lateral tail vein. For wild-type transplants (WT-HSCT), mice received 1-2×107 untransduced total bone marrow cells.
- Engraftment of donor haematopoietic stem cells was assessed at 4 weeks post-transplant in peripheral blood. Cells were stained with anti-mouse CD45.1-PE (donor
- HSCs), CD45.2-FITC (recipient HSCs), CD3-Pe-Cy5 (T-cell), CD19-APC-Cy7 (B-cell) and CD11b-Pe-Cy7 (macrophage/microglia) (BD Pharmingen, Oxford, UK) in a 5% solution of ToPro3 Iodide (ThermoFisher Scientific, Paisley, UK) and analysed on a BD FACS Canto II flow cytometer (BD).
- At 8 months of age, mice were anesthetized and transcardially perfused with 37° C. phosphate buffered saline to remove blood from organs. One brain hemisphere was fixed in 4% paraformaldehyde for 24 hours, transferred to a 30% sucrose, 2 mmol/l MgCl2/phosphate-buffered saline solution for 48 hours before freezing at −80° C. Pieces of brain, spleen, heart, kidney, muscle and liver were snap-frozen on dry ice and stored at −80° C. For IDS enzyme activity assays, samples were homogenised and sonicated in homogenisation buffer (0.5 mol/l NaCl, 0.02 mol/l Tris, 0.1% Triton-X100, pH 7-7.5) before centrifugation at 14,000 rpm at 4° C. for 30 minutes. Bone marrow samples were collected by flushing one tibia and femur with 1
ml 2% FBS/PBS, filtered using a 70 μm filter and lysed using red blood cell lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2-7.4). Supernatant was collected and stored at −80° C. Genomic DNA used for organ VCN analysis was extracted using GenElute Mammalian Genomic DNA Miniprep kit. - IDS enzyme activity was measured in a two-step protocol using the fluorescent substrate MU-aldoA-2S (Carbosynth, Compton, UK) and laronidase (Aldurazyme, Genzyme) as the second step substrate as previously described (37). The amount of starting material was standardised to 20 μg of total protein for plasma, 40 μg for liver, spleen and bone marrow, and 60 μg for brain using a BCA assay (Thermo Fisher).
- Soluble brain fractions were collected and processed as previously described (38). Briefly, brain tissue was homogenised mechanically and Pronase-treated (1 mg/tissue) in 3 ml PBS for 4 hours at 37° C. 30 μl of TritonX100 was added to each sample for a 1% final concentration and incubated for an hour at room temperature prior to a second addition of 1 mg of Pronase for 4 hours at 37° C. Samples were loaded onto a pre-equilibrated DEAE-Sephacel column and hyaluronan was removed by washing the column with 50 ml of 0.25M NaCl/20 mM NaH2PO4H2O (pH 7). GAGs were eluted with 5 ml 1.5M NaCl/20 mM NaH2PO4H2O (pH 7), desalted using a PD10 column (Amersham, GE Healthcare) and freeze-fried.
- HS chains were digested using 5mIU each of heparinase I, II and III (Seikagaku, Tokyo, Japan) in 100 μl of 0.1M sodium acetate and 0.1M calcium acetate (pH 7).
- Resulting disaccharides were freeze-dried, re-dissolved in 20 μl of 0.1M 2-aminoacridone (AMAC) in 85% Me2SO/15% acetic acid (v/v) and incubated at room temperature for 20 minutes. 20 μl of NaBH3CN was added to each sample and incubated overnight at room temperature. AMAC-labelled disaccharides were separated by reverse phase high-performance liquid chromatography using a Zorbax Eclipse XDB-C18 column (2.1×500 mm, 3.5 μm) (Agilent Technologies, Stockport, UK).
- Levels of IL-1α, MCP-1, MIP-1α and RANTES were measured in whole brain extracts at 8 months of age (n=6/group) using BD Cytometric Bead Array (CBA) Flex Set kits (BD Biosciences, Oxford, UK) (40). Analysis was performed on a FACS Canto II flow cytometer (BD). Identification of the singlet bead population was performed using the FSC vs SSC plot, and each individual cytokine bead was separated using APC and APC-Cy7, with cytokine levels measured using PE. The results were exported and analysed using FCAP Array software (BD). Brain protein concentrations were obtained using the BCA assay and cytokine levels were standardised to protein level for each sample.
- The rotarod test was used to evaluate motor coordination and balance at 32 weeks of age as previously described with minor modifications (41). Male mice (WT, n=16, MUT, n=12, treatment groups n=12-16) were trained on the rotarod (Ugo Basile, Varese, Italy) across three training trials (4 rpm for 120 seconds; 4 rpm for 300 seconds; 4-40 rpm over 300 seconds) with a 30 minute interval between each session. Three test trials were carried out 24 hours post-training. For test trials, the rotarod rotated at an accelerating speed of 4 to 40 rpm over 300 seconds, with a 5 minute rest between each trial. Latency to fall was recorded for all training and test trials, and latency to fall off was calculated as percentage of total trial time.
- Spatial working memory was assessed in all mice at 32 weeks of age using the spontaneous alternation test (41, 42). Spontaneous alternation was assessed in a single trial in a Y-maze consisting of three identical arms. The test mouse was placed in the middle of the three arms and allowed to explore freely. Spontaneous alternation was described as successive entries into three arms, in overlapping triplet sets. The effect was calculated as percent alternation=[no. of alternations/(total number of arm entries−2)]×100.
- Control and treated mice were anesthetised using isoflurane and radiographed (45 keV) using the Bruker InVivo Xtreme system fitted with a high sensitivity, back-thinned back-illuminated 4MP, 16-bit, digital CCD camera. X-ray images were analysed using ImageJ software for individual bones widths.
- Statistical analysis was performed using GraphPad Prism 7 software (La Jolla, CA, USA). Two-tailed parametric unpaired t-tests were applied for individual group comparisons with significance set at p<0.05. One-way ANOVAs were performed for multi-group analysis followed by Tukey's multi-comparisons test.
- During the experiments, the inventors sought to develop a novel MPS II-specific sulphatase enzyme that was able to efficiently cross the BBB through the use of the LDLR via receptor-mediated transcytosis. Novel lentiviral vectors encoding for human IDS alone, or human IDS linked to the human ApoE receptor-binding region as a tandem repeat, were constructed under the human myeloid-specific CD11b promoter (as illustrated in
FIG. 1 a ). - This sulphatase was modified by adding an invariant flexible linker to the C-terminal of the IDS gene, followed by the codon-optimised sequence of the receptor-binding portion of human ApoE as a tandem repeat (as illustrated in
FIG. 1 b ). Typically, the addition of a linker and peptide can alter protein folding and detrimentally affect enzyme activity. - To verify that the inventive construct still allowed for IDS overexpression and secretion, a human microglial cell line (CHME3) was transfected with plasmid DNA expressing either LV.IDS or LV.IDS.ApoEII. 26-fold and 24-fold increases in cellular activity were observed with LV.IDS and LV.IDS.ApoEII, respectively (as shown in
FIG. 1 c ). More importantly, increases of 84-fold and 81-fold in secreted IDS activity were detected 72 hours post-transfection (FIG. 1 d ). Notably, this demonstrates that the C-terminal modifications do not negatively impact secretion or expression of the modified IDS enzyme in vitro. A significantly increased uptake of IDS.ApoEII over IDS in mouse endothelial bEND.3 cells after 24 hours (FIG. 1E, 1F ) was detected, predominantly, but not exclusively, via M6P receptors (FIG. 1F ) - 4×105 lineage-depleted haematopoietic stem cells (HSCs) were transplanted from MPS II donors transduced with either LV.IDS or LV.IDS.ApoEII, expressing IDS or IDS.ApoEII, into 16 busulfan-conditioned 6-8 week-old MPS II mouse recipients (as illustrated in
FIG. 2 a ). Unmodified total bone marrow cells were also injected into fully myelo-ablated MPS II recipients, equivalent to an allogeneic stem cell transplant, and are henceforth referred to as WT-HSCT. - IDS activity and vector copy number (VCN) were measured in lineage-depleted HSCs (lin-HSCs) isolated from colony-forming unit (CFU) assays prior to transplant. The experiments demonstrated mean vector copy numbers of 3.1 and 3.8 in the LV.IDS- and LV.IDS.ApoEII-transduced HSCs (as shown in
FIG. 2 b ) and overexpression of IDS enzyme by 124-fold and 152-fold over WT, respectively (as shown inFIG. 2 c ). These data demonstrate a positive correlation between the number of vector genome integrations and enzyme overexpression in haematopoietic cells. Flow cytometry analysis of peripheral WBCs at 4-weeks post-transplant demonstrated full engraftment of transduced cells into MPS II recipients, achieving between 80-100% of donor CD45.1+ cells (as shown inFIG. 2 d ). - To assess therapeutic efficacy of this novel gene therapy in MPS II, 6 animals from each group were sacrificed at 8 months of age for biochemical analysis of central and peripheral organs. Vector integrations were detected in total BM, WBCs, spleen and brain, with a significantly lower mean in LV.IDS.ApoEII-treated mice in WBCs only (as shown in
FIG. 2 e ). A small number of animals consistently showed lower VCNs in all organs assessed, but received modified HSCs in separate transplantation procedures. Supra-physiological levels of IDS were observed in BM, plasma and spleen for both LV.IDS- and LV.IDS.ApoEII-treated groups. IDS enzyme activity levels in the brain were also elevated compared to untreated MPS II animals, and are equivalent to between 1.5% and 8% of normal IDS activity in WT brains. The WT-HSCT transplants restored IDS levels equivalent to WT in BM, plasma and spleen only, whilst no noticeable increase in IDS activity was detected in the brain over untreated MPS II animals. - Advantageously, IDS activity in plasma of LV.IDS.ApoEII-treated animals was 3-fold higher than in the LV.IDS-treated group, suggesting potential alterations in enzyme stability and circulation time, secretion or uptake into cells (as shown in
FIG. 2 f ). Furthermore, positive correlations between VCN and IDS enzyme activity levels further suggests that enzyme overexpression is driven by increases in genome integration of the IDS gene (FIG. 2 g ). However, correlations between WBC VCN and IDS activity in plasma show significant differences between LV.IDS and LV.IDS.ApoEII groups, where low VCN in LV.IDS.ApoEII WBCs results in IDS levels that are higher than in any of the LV.IDS-treated mice, suggesting mechanistic differences in enzyme production, uptake or secretion. Additionally, higher IDS levels in plasma of LV.IDS.ApoEII-treated animals does not yield higher IDS enzyme levels in brain, as enzyme levels in the brain are equivalent in both LV-treated groups (as shown inFIG. 2 f ). The clearance rate of injected enzyme in plasma was similar between the IDS and IDS.ApoEII groups (FIG. 2J ). Positive correlations between VCN and IDS enzyme activity levels in BM, spleen, brain, lung, liver and heart, was observed with nearly equivalent activity/VCN for both IDS and IDS.ApoEII, suggesting that enzyme overexpression is driven by increases in genome integration of the IDS gene (FIG. 2K ). - A value of 15.41 units/VCN of enzyme activity was detected in LV.IDS.ApoEII compared to 2.56 units/VCN in LV.IDS in plasma, suggesting that IDS enzyme activity in plasma is significantly increased by fusion of the ApoEII residue. This increase in enzyme activity in IDS.ApoEII is further demonstrated by comparing IDS enzyme activity to IDS protein in plasma, where IDS.ApoEII appears to be more active per unit of IDS protein (
FIG. 2M ). - The dysfunction and uncontrolled accumulation of primary storage material in lysosomes in MPS II is likely to have a profound impact on lysosomal regulation and subsequent homeostasis. Importantly, neurodegeneration is associated with lysosomal dysfunction and impaired autophagy. In disease states such as MPS II, endogenous lysosomal enzymes can compensate for the deficiency of another lysosomal enzyme. Elevated levels of the lysosomal hydrolase 8-hexosaminidase were detected in the plasma (2-fold over WT), spleen (1.53-fold over WT) and brain (2-fold over WT) of untreated MPS II animals (
FIG. 2N-P ). Plasma, spleen and brain levels of β-hexosaminidase were fully normalized back to WT levels in both LV.IDS- and LV.IDS.ApoEII-treated groups (FIG. 2N-P ). WT-HSCT normalized 8-hexosaminidase levels in plasma and spleen (FIG. 2N, 2O ), and ameliorated levels in the brain without achieving complete normalization to WT levels (FIG. 2P ). - HS and CS/DS glycosaminoglycans were purified from brain samples, and analysed and quantified by reverse-phase HPLC. A 6-fold increase in total HS was detected in brains of MPS II mice and mice treated with WT-HSCT (
FIG. 6A ). Mice treated with LV.IDS showed a decrease in total HS accumulation in the brain to approximately 3-fold of WT levels. Most importantly, LV.IDS.ApoEII-treated mice showed a complete normalization of brain HS levels back to WT levels and significantly lower levels of HS when compared to LV.IDS (FIG. 6A ). - HS composition analysis in MPS II mice showed that 31.1% of brain HS consisted of the fully sulfated UA(2S)-GIcNS(6S), compared to 12.3% in control WT mice (
FIG. 6B ). In WT mice, these generally form clusters with other sulfated disaccharides along the chain, with significant increases in sulphation along the entirety of the HS chain in MPS II mice. This trend was reversed with WT-HSCT, LV.IDS and most effectively by LV.IDS.ApoEII. Similarly, increases in UA(2S)-GIcNS from 16.8% in WT mice to 31.1% in MPSII mice were observed, and fully corrected down to 18.4% in the LV.IDS.ApoEII group only. - It was also observed a significant reduction in total brain CS/DS levels in LV.IDS.ApoEII mice when compared to MPS II (Supplementary
FIG. 2A ); although no significant differences were detectable between WT and MPS II mice. increases in UA(2S)-GaINAc(4S) from 1.03% in WT mice to 6.5% in MPS II mice were detected, with complete correction obtained in the LV.IDS.ApoEII group. - The effects of increased IDS enzyme levels in the brains of transplanted MPS II mice at 8 months of age (6 months post-transplant) on lysosomal enlargement and substrate accumulation in neurons (NeuN) using the lysosomal marker LAMP2 were then determined. WT animals displayed weak, punctate and perinuclear LAMP2 staining that only partially co-localized with NeuN in the motor cortex (layer V/VI). Untreated MPS II and WT-HSCT-treated animals displayed strong co-localized staining of NeuN and LAMP2 in the motor cortex, caudate putamen, hippocampus and amygdala, suggesting a heavy lysosomal burden in neurons or satellite glial cells (
FIG. 6C ). LV.IDS mediated improvements in the cerebral cortex, caudate putamen and amygdala, with engorged lysosomal compartments in the hippocampus still visible, suggesting only a partial correction of primary substrate accumulation, which strongly correlates to the levels of HS detected in the brain (FIG. 6A, 6B ). LV.IDS.ApoEII fully normalised the increased LAMP2 staining in the cortex, caudate putamen and hippocampus, and considerably reduced the amount of lysosomal burden in the amygdala (FIG. 6C ). - Astrocytes have been found to mediate a strong neuro-inflammatory response in MPS disorders, which translates into reactive gliosis, astrogliosis and increased levels of inflammatory cytokines. Brain coronal sections of control and treated MPS II mice were stained with the astrocytic marker GFAP (glial fibrillary associated protein; green) and LAMP2 (red). Significantly more GFAP staining was observed in untreated MPS II than in WT mice in the cortex, caudate putamen and amygdala, indicative of extensive astrogliosis (
FIG. 7A ). Additionally, strong co-localization of GFAP and LAMP2 was observed in the caudate putamen, hippocampus and amygdala in untreated and WT-HSCT mice (FIG. 7A ), suggesting significant lysosomal substrate accumulation in astrocytes in addition to neurons (FIG. 6C ). LV.IDS.ApoEII was able to fully abrogate astrogliosis and decrease LAMP2 staining back to WT levels in the cortex, caudate putamen, hippocampus and amygdala, correlating to decreases in substrate storage and inflammatory cytokines (FIG. 6A, 6B, 6A -D). Similarly, LV.IDS decreased the number of reactive astrocytes present in the cortex, caudate putamen and amygdala. - To understand whether CNS and skeletal phenotype in the MPS II mouse model could be ameliorated with LV.IDS- or LV.IDS.ApoEII-modified HSCs, functional studies of cognition and sensorimotor performance were performed at 8 months of age, equivalent to 6 months post-transplant, on all treated animals in each group. Cognitive evaluation of spatial working memory was evaluated using the Y-maze test, which exploits their innate preference to explore novel arms over recently explored arms over 10 minutes (as illustrated in
FIG. 3 a ). - Neurocognitive assessment showed complete normalisation of spontaneous alternation in LV.IDS.ApoEII-treated mice, but not in the LV.IDS-treated or WT-HSCT groups (
FIG. 3 b ). This suggests not only complete correction of cognitive dysfunction seen in the MPS II mouse model using LV.IDS.ApoEII, but also shows the prevention of further cognitive deterioration associated with progressive MPS II disease. Interestingly, WT-HSCT has no positive impact on the cognitive symptoms associated with MPS II; further highlighting that WT-HSCT may not be suitable to treat the brain in MPS II. The total number of entries into the different arms of the Y-maze can also be used as a proxy measure of overall activity. No differences in the number of total entries were detected between all tested groups, suggesting a real phenotypic rescue of cognitive symptoms in LV.IDS.ApoEII-treated animals (as shown inFIG. 3 c ). - Control and treated mice also underwent testing on the rotarod, a well-established test for sensorimotor coordination and balance in movement disorders in rodents (as shown in
FIG. 3 d ). 8-months-old MPSII mice showed a reduction in performance on the accelerating rod as previously described. This was entirely rescued by all transplant treatments, including WT-HSCT (as shown inFIG. 3 e ). - Cytometric bead arrays (CBA) were used to quantify a number of inflammatory cytokines associated with chronic neuro-inflammation from whole brain extracts of control and treated mice at 8 months of age. For the first time, we identified significant increases in macrophage inflammatory protein (MIP-1α/CCL3), interleukin 1α (IL-1α) protein, RANTES (CCL5) and monocyte chemoattractant protein (MCP-1/CCL2) in untreated MPS II animals (as shown in
FIGS. 4 a, 4 b, 4 c, 4 d ). MIP-1α, IL-1α and RANTES protein levels were normalised with LV.IDS.ApoEII, and only partially with LV.IDS, and MCP-1 levels remained elevated for all groups (as shown inFIG. 4 b ). - Additionally, we observed a 30-fold and 25-fold increase in isolectin B4 (ILB4)-positive cells in the cortex and striatum of untreated MPS II mice, respectively (
FIG. 4E, 4F, 4G ), suggesting extensive activation of microglia and subsequent neuro-inflammation. Interestingly, both WT-HSCT and LV.IDS reduced ILB4 staining to 14-fold and 12-fold of WT levels in the cortex (FIG. 4F ), and to 15-fold and 13-fold of WT staining in the striatum (FIG. 4G ), respectively. Most importantly, LV.IDS.ApoEII was able to completely normalize the number of activated microglia in both the cortex and striatum (FIG. 4F , 4G), which strongly correlates with the reduction of neuro-inflammation cytokines previously observed and the full abrogation of astrocytosis in LV.IDS.ApoEII. - Overall, this suggests that the release of neuro-inflammatory cytokines and chemokines, reactive astrogliosis and microglial activation in MPS II can be fully abrogated by LV.IDS.ApoEII, and only partially with LV.IDS.
- HS GAGs were purified from control and treated brains of MPS II mice and depolymerised into individual HS disaccharides using bacterial heparinase enzymes followed by fluorescent-tagging of reducing ends of individual disaccharides using AMAC.
- Reverse-phase HPLC separation was used to quantify and determine the individual contributions and sulphation patterns of each HS disaccharide.
- HPLC analysis allows for the relative levels of total HS to be calculated between WT, untreated MPS II and all treatment groups (as shown in
FIG. 4 e ). A 6-fold increase in total HS was detected in brains of MPS II mice and mice treated with WT-HSCT (p<0.0001). Interestingly, mice treated with LV.IDS showed a decrease in total HS accumulation in the brain to approximately 3-fold of WT levels. Most importantly, LV.IDS.ApoEII-treated mice showed a complete normalisation of brain HS levels back to WT levels (as shown inFIG. 4 e ). - HS composition analysis showed significant increases of tri-sulphated disaccharide UA(2S)-GIcNS(6S), and increases in UA(2S)-GIcNS in untreated MPS II brains (as shown in
FIG. 4 f ). This trend was partially reversed with WT-HSCT and LV.IDS, although full correction back to WT levels was only obtained in the LV.IDS.ApoEII group. - Mono-sulphated HS disaccharides showed a significantly different trend; where untreated MPS II and WT-HSCT-treated levels of UA-GIcNS were lower than in WT brains (as shown in
FIG. 4 f ). This was partially improved with the LV.IDS treatment, but only fully corrected in the LV.IDS.ApoEII group. - Total body X-rays under full anaesthesia were performed on control and treated mice to obtain robust data on the extent of skeletal symptoms in the MPS II mouse model. Widths of zygomatic arches and appendicular long bones (humeri and femurs) were measured using ImageJ imaging software.
- The width of the zygomatic arches, which are significantly increased in untreated MPS II animals, were reduced to WT dimensions in all transplanted groups, including WT-HSCT (as shown in
FIGS. 5 a, 5 b ). Humerus widths were significantly reduced in WT-HSCT and LV.IDS groups, although full correction was only obtained in the LV.IDS.ApoEII-treated animals (as shown inFIG. 5 c ). Moreover, femur widths in all treated animals showed no significant differences when compared to WT animals, suggesting significant skeletal rescue. - Elevated levels of MCP-1, MIP-1α and RANTES were detected in the livers of MPS II mice at 8 months of age, which were completely abrogated by WT-HSCT, LV.IDS-or LV.IDS.ApoEII treatments (
FIG. 5E -5G). These data suggest that WT-HSCT, LV.IDS and LV.IDS.ApoEII produce sufficient amounts of peripheral enzyme to fully correct chronic peripheral inflammation in MPS II mice. - The expression of Nppb and Myh7, two markers associated with cardiomyopathies and cardiac pathology, which could be indicators of higher risks of heart failure in the MPS II mouse model, were investigated. The expression of Nppb, which encodes for the brain natriuretic peptide (BNP) that is secreted from the ventricles and regulates myocyte stretching and blood pressure, was found to be approximately 16-fold higher in MPS II than in WT male mice (
FIG. 5H ). Nppb expression was fully stabilized back to WT levels in WT-HSCT, LV.IDS and LV.IDS.ApoEII groups (FIG. 5H ). Myh7 expression, primarily found in embryonic heart and encodes for myosin heavy chain beta as a key component of cardiac muscle and type I muscle fibers, was elevated in untreated MPS II animals. Myh7 expression in WT-HSCT, LV.IDS and LV.IDS.ApoEII groups was similar to WT expression (FIG. 5I ). - To study whether gene-modified cells were able to mediate tolerance to human IDS post-transplant, we analysed plasma from mice that received full myeloablative conditioning followed by either LV.IDS or LV.IDS.ApoEII transplant, both over-expressing human IDS, for IgG antibodies against human IDS. Overall IDS-specific IgG titers in LV.IDS and LV.IDS.ApoEII groups remained in the normal range and did not contribute to an immune response to the enzymes (
FIG. 5J ). - Following the observed increase in enzyme activity in plasma and the increased enzyme activity per VCN in LV.IDS.ApoEII-treated mice (
FIG. 2 f, 2 j ), we hypothesized that the circulation time of enzyme might be increased. Equivalent levels of IDS and IDS.ApoEII enzyme were injected into MPS II mice and protein levels monitored by ELISA (FIG. 9A ). Interestingly, enzyme clearance rate, whether from degradation or uptake into organs, was similar between the IDS and IDS.ApoEII groups and was effectively cleared in both groups by 30 minutes. - Next levels of active enzyme in the plasma compared to total IDS protein were compared and measured by ELISA, hypothesizing that the conformation of the enzyme may be altered with the addition of the ApoEII residue, conferring additional protection against degradation. IDS.ApoEII appeared to be more active per unit of IDS protein in plasma (
FIG. 9B ). This may suggest the active site of native IDS enzyme is rapidly degraded in plasma whereas the ApoEII addition is protective, effectively prolonging enzyme activity in vivo. - The BBB endothelial cell line bEND.3 was used to determine whether there was any difference in enzyme uptake by endothelial cells. These cells produce an effective BBB layer in transwells (
FIG. 9C ) and express both LDLR and LDLR-related protein 1 (LRP1) receptors (FIG. 9D, 9E ). In order to ensure that each enzyme has a similar M6P status to that of the HSCGT produced enzyme, we used IDS and IDS.ApoEII enzyme secreted into the media after transfection of CHME3 human microglial cells and standardized by ELISA. In monolayer culture, we compared the uptake of IDS versus IDS.ApoEII into bEND.3 cells, identifying a 4.7-fold increase in cellular uptake with the addition of the ApoEII peptide (FIG. 9F ). The uptake and transcytosis of IDS or IDS.ApoEII across polarized cell layers of bEND.3 endothelial cells in transwells to mimic the BBB were then compared. 2.6-fold increases in uptake were apparent, similar to when cells were grown in monolayer, together with a 1.5-fold increase in transcytosis to the basolateral side of the transwell (FIG. 9G, 9H ). - In addition, blockade of ApoE dependent receptors using ApoE or blockage of M6P receptors using M6P (
FIG. 9I ), revealed that IDS.ApoEII was preferentially and unexpectedly taken up via M6P receptors, although blockade with ApoE peptide also significantly inhibited uptake of IDS.ApoEII by approximately 30%. The ApoEII peptide sequence also codes for a HS site, required as a co-receptor for receptor/ligand binding of ApoE to its receptors, including LDLR and LRP1 (Ji et al, 1993). Heparinase pre-treatment of cells also resulted in a reduction in IDS.ApoEII uptake by approximately 30%, similar to results with ApoE peptide, suggesting that ApoE/HS may also be important in uptake and transcytosis across bEND3 cells. - The addition of the linker and ApoEII peptide did not change the expression, production or secretion of the IDS enzyme in vitro, but produced supra-physiological levels of IDS enzyme in transduced HSCs using both LV.IDS and LV.IDS.ApoEII vectors for similar vector copy number. Complete engraftment of CD45.1+ donor cells (>80%) was obtained using full myelo-ablative conditioning using busulfan in all transplanted animals, with no significant differences in downstream in vitro differentiation assays at the time of transplant (data not shown).
- Surprisingly, IDS enzyme activity levels in plasma in the LV.IDS.ApoEII group were approximately 3-fold higher than in LV.IDS, even with lower VCN in WBCs. This translates to higher enzyme activity per copy in the LV.IDS.ApoEII group, suggesting that the ApoEII residue stabilizes or improves activity by changing its conformation, and appear to provide a protective effect against enzyme inactivation, but not clearance in plasma (
FIG. 8 ). A higher uptake of IDS.ApoEII in bEND.3 cells compared to unmodified IDS was detected and this was believed to be mediated predominantly by M6PR. The receptor-binding portion of apoE used in the IDS.ApoEII fusion enzyme (residues 142-147) is able to form a high affinity binding complex with an octasaccharide HS fragment composed of four repeats of UA(2S)-GIcNS(6S), which are abundant on endothelial cell surfaces and even more abundant in MPS II. HS typically acts as a co-receptor in many receptor ligand interactions and increased binding to HS proteoglycans (HSPG) through ApoEII could mediate an increase in cellular uptake through the LDLR, LDLR-related protein 1 (LRP1), M6P or by direct uptake of an apoE-HSPG complex. - Similar amounts of enzyme activity within the brain between the LV.IDS and LV.IDS.ApoEII groups were detected, but complete correction only in LV.IDS.ApoEII with improved clearance of LAMP2 from neurons and astrocytes. One explanation for this is that enzyme uptake from the interstitial space may be more efficient using IDS.ApoEII, thereby correcting resident brain cells much more effectively than unmodified IDS whilst maintaining the same overall levels (
FIG. 8 ). - Full correction of primary storage elevations and a global normalisation of the sulphation patterning, which plays a major role in neuro-inflammation, were observed in LV.IDS.ApoEII-treated animals. Partial correction of the primary HS storage in the brain is insufficient to correct cognitive behavior. The accumulation of HS in MPS II likely could provide one of the first signals that trigger neuro-inflammation and exacerbate neurodegeneration. The sulphation patterning also plays a crucial role in cellular function and HS-binding homeostasis, as 6-O- and 2-O-sulphated HS are essential for signaling of fibroblast growth factor and stromal cell derived factor-1 (CXCL12). Indeed, abnormal excess HS in MPS I was shown to reduce migration of HSCs under limiting conditions via sequestration of CXCL12 (42). In the context of this study, increases in sulfated disaccharides in brain tissue of diseased animals could promote improved cellular uptake of the IDS.ApoEII enzyme, thereby enhancing enzyme targeting to diseased cells.
- A significantly increased uptake of IDS.ApoEII in bEND.3 cells compared to IDS via both an ApoE/HS based mechanism and via M6P receptors was observed. The use of multiple targeting mechanisms could mediate more efficient targeting to enzyme-deficient cells throughout the body as well as across the BBB. The receptor-binding portion of ApoE used here is able to form a high affinity binding complex with an octasaccharide HS fragment composed of four repeats of UA(2S)-GIcNS(6S), which are abundant on endothelial cell surfaces and even more abundant in MPS II. In the context of this study, increases in sulfated disaccharides in brain tissue of diseased animals could promote improved cellular uptake of the IDS.ApoEII enzyme, via the HS binding motif in the ApoEII peptide, thereby enhancing enzyme targeting to diseased cells. HS typically acts as a co-receptor in many receptor ligand interactions and increased binding to HS proteoglycans through ApoEII could mediate an increase in cellular uptake through the LDLR, LRP1, M6P or by direct uptake of an ApoE-HSPG complex. Improved plasma stability coupled with increased BBB uptake and transcytosis could together account for the normalization of HS and DS storage, as well as several other neuropathologies in the brain seen with LV.IDS.ApoEII, in the absence of significant differences in brain enzyme amount. A similar effect of increased uptake, clearance and cell association for similar enzyme activities have been seen in MPS IIIB and Pompe disease using enzymes coupled to GILT tags targeting an alternative epitope of M6P via an IGFII receptor directed peptide. In this study small increases in brain enzyme activity with SGSH.ApoB was shown with no significant changes over native IDS.
- Neuro-inflammation is commonly reported in LSDs, likely caused by the accumulation of various undegraded molecules, which cooperatively activate and perpetuate a neuro-inflammatory milieu that may exacerbate the disease itself. MPS II mice elicit a strong inflammatory response in the brain, with elevated levels of MIP-1α, IL-1α, RANTES and MCP-1. MIP-1α, IL-1α and RANTES levels were fully normalised in the LV.IDS.ApoEII group, with only partial decreases in LV.IDS-treated mice. Interestingly, MCP-1 levels remained elevated in MPS II and all busulfan-conditioned mice. As we have previously shown, busulfan-conditioning leads to long-term increases in MCP-1 levels in the brain, a key mediator of cell transmigration to the CNS, and exerts a long-term trans-migratory effect. Approximately 20% of intravenously injected busulfan can cross the BBB, driving an even stronger pro-migratory MCP-1 response, which may ultimately facilitate the transmigration of donor-derived leukocytes across the BBB into the CNS in MPS II mice and provide additional means of trafficking enzyme into brain parenchyma.
- Microglial activation and astrocytosis are commonly reported in MPS disorders, including this study. We observed a complete abrogation of GFAP and LAMP2 staining in the cortex, caudate putamen, hippocampus and amygdala of LV.IDS.ApoEII mice, with only partial correction of the same areas in the LV.IDS group. Furthermore, complete normalisation of activated microglia was observed in the cortex and striatum of LV.IDS.ApoEII-treated mice, with only a 50% reduction in LV.IDS. LV.IDS.ApoEII treatment is comparable to the correction of astrogliosis and microglial activation reported using direct AAV9-IDS injection into the CSF (15). Peripheral inflammation was detected in livers of MPS II mice, with stark elevations in the levels of MCP-1, MIP-1α and RANTES, and was abrogated by all transplants, indicating that peripheral IDS enzyme levels obtained with an allogeneic transplant can mediate a reduction in inflammation in the periphery.
- As a sensitive and widely accepted paradigm of exploratory behavior and spatial working memory, the Y-maze accounts for potential physical impairments in MPS II mice, unlike the Barnes maze, which may be invalidated by differential physical performance. Full behavioural correction of cognitive deficits was observed in the LV.IDS.ApoEII group alongside normalisation of coordination and balance. We hypothesise that cognitive improvements likely stems from a combination of factors; a reduction in primary storage of HS alongside full abrogation of chronic neuro-inflammation, astrogliosis and microglial activation, all of which were only observed in LV.IDS.ApoEII-treated animals. The rescue of coordination and balance can be attributed to either central or peripheral rescue, or a combination thereof. Most importantly, this further highlights that the addition of the ApoE tandem peptide is absolutely necessary to target IDS enzyme to the brain to provide a full correction of the neurocognitive aspect in MPS II mice.
- The present inventors and others have reported progressive skeletal abnormalities in the MPS II mouse model, such as enlargement of craniofacial bone structures and femurs), correlating with the dysostosis multiplex seen in MPS II patients. As little enzyme is targeted to the cartilage or bone lesions, ERT using idursulfase showed limited benefits in joint pain, stiffness, or range of motion, although earlier treatments could provide benefits. In our study, the widths of zygomatic arches, humerus and femurs were significantly reduced in all transplanted animals, including WT-HSCT, suggesting that some level of enzyme can penetrate bone tissue if treated at an early time point when skeletal phenotype remains mild. This is partly comparable to liver-directed AAV2/8TBG-IDS gene therapy, where craniofacial abnormalities were also corrected . Importantly, it is likely that sustained availability of enzyme to the skeleton and joints from an early time point is required for clinical improvements.
- Cardiac involvement in MPS II ranges from progressive valvular pathology, left ventricular hypertrophy, increased wall thickness to systemic hypertension, yielding a complex cardiac phenotype that remains difficult to treat (49). A plethora of factors can trigger the activation of transcription factors, co-regulators and microRNAs that will alter cardiac gene expression. HS GAGs also partly regulate Sonic Hedgehog (Shh), involved in heart ontogenesis and cardiac regeneration, which is downregulated alongside Ptch1, FoxM1 and Bmp4 in MPS II mice. Expression of Nppb and Myh7, two genes previously implicated with heart failure in MPS IIIB mice, was elevated up to 18-fold and 9-fold over WT levels respectively, suggesting a significant deregulation of cardiac genes and cardiac pathways in MPS II mice that is rescued with all transplants. Hence, sustained delivery of IDS enzyme in the periphery can benefit heart tissue and restore normal cardiac gene expression, if only partially. Overall, it has been shown for the first time that the expression of cardiac genes involved in heart failure can be modulated to WT levels by transplanting HSCs expressing either endogenous or supra-physiological levels of IDS enzyme, and that this may be a significant step in treating the cardiorespiratory phenotype in MPS II patients.
- Immunologically foreign proteins and enzymes such as ERT can trigger the release of inhibitory antibodies that may decrease therapeutic efficacy, although molecular and cellular chimerism after HSCT can induce tolerance to donor-specific antigens. IgG antibodies against human recombinant IDS in plasma of LV.IDS and LV.IDS.ApoEII-treated mice were not detected, and no adverse symptoms identified that could be attributed to neutralising antibodies. Overall, this is a strong indication that hematopoietic stem cell gene therapy (HSCGT) can induce tolerance and that both enzymes produced are well tolerated by the immune system. Lastly, the addition of the ApoEII peptide residue does not generate increased immune sensitivity when compared to unmodified IDS.
- Significantly, the addition of the apoE tandem repeat to human IDS allows for complete correction of the neuro-inflammation, neurodegeneration and cognitive behaviour in the MPS II mouse model, likely by a combination of increased uptake and enzyme stabilisation mechanisms. Previous gene therapy approaches have highlighted the therapeutic potential of BBB-fusion enzymes with the receptor-binding domain of other Apo complexes such as ApoB and ApoE to correct brain pathology in disease models of LSDs and their promising clinical use for MPS disorders. This is the first study highlighting the combined use of HSCGT and the ApoEII-fusion enzyme to fully correct the neurological, skeletal, inflammatory and behavioural phenotypes in MPS II mice. The experiments show the suitability HSCGT using ApoEII-modified enzyme for the treatment of MPS II patients.
- The forgoing embodiments are not intended to limit the scope of the protection afforded by the claims, but rather to describe examples of how the invention may be put into practice.
-
Sequence Listings (colDS DNA sequence) SEQ ID No. 1 atgcctccac ctagaactgg aagaggcctg ctgtggctgg gcctggtgct gtctagtgtg 60 tgtgtggccc tgggcagcga gacacaggcc aacagcacaa ccgacgccct gaacgtgctg 120 ctgatcatcg tggacgacct gaggcctagc ctgggctgct acggcgataa gctcgtgcgg 180 agccccaaca tcgatcagct ggcctctcac agcctgctgt tccagaacgc attcgcacag 240 caggcagtgt gcgcccccag cagagtgtct ttcctgaccg gcagaaggcc cgacaccacc 300 cggctgtacg acttcaacag ctactggcgg gtgcacgccg gcaacttcag caccatcccc 360 cagtacttca aagaaaacgg ctacgtgacc atgagcgtgg gcaaggtgtt ccaccccggc 420 atcagctcca accacaccga cgacagcccc tacagctggt ccttcccacc ctaccacccc 480 agcagcgaga agtacgagaa caccaagacc tgcagaggcc ccgacggcga gctgcatgcc 540 aatctgctgt gccccgtgga cgtgctggat gtgcctgagg gaaccctgcc cgacaagcag 600 tctaccgagc aggccattca gctgctggaa aagatgaaga ccagcgccag ccccttcttc 660 ctggccgtgg gctatcacaa gccccacatc cctttcagat accccaaaga gttccagaag 720 ctgtaccccc tggaaaacat caccctggcc cccgatcctg aggtgccaga tggactgcct 780 cccgtggcct acaacccctg gatggacatc cggcagcgcg aggatgtgca ggccctgaat 840 atcagcgtgc cctacggccc catccccgtg gatttccagc ggaagatccg gcagagctac 900 ttcgccagcg tgtcctacct ggacacccaa gtgggcagac tgctgagcgc cctggacgat 960 ctgcagctgg ccaactccac catcattgcc ttcaccagcg accacggctg ggccctggga 1020 gaacatggcg agtgggccaa gtacagcaac ttcgacgtgg ccacccacgt gcccctgatc 1080 ttctacgtgc caggcagaac cgccagcctg cctgaggctg gcgagaagct gttcccttac 1140 ctggacccct tcgacagcgc ctcccagctg atggaacctg gcagacagag catggacctg 1200 gtggaactgg tgtccctgtt ccccacactg gccggactgg ctggactgca ggtgccccct 1260 agatgtcccg tgcctagctt tcacgtggaa ctgtgcagag agggcaagaa cctgctgaag 1320 cacttccggt tccgggacct ggaagaagat ccctacctgc ccggcaaccc cagagagctg 1380 atcgcctaca gccagtaccc cagacccagc gacatccctc agtggaacag cgacaagccc 1440 agcctgaagg acatcaagat catgggctac agcatccgga ccatcgacta ccggtacacc 1500 gtgtgggtgg gattcaaccc cgacgagttc ctggccaatt tctccgacat ccacgccggg 1560 gagctgtact tcgtggacag cgatcccctg caggaccaca acatgtacaa cgacagccag 1620 ggcggcgacc tgttccagct gctgatgccc 1650 (Wild Type IDS DNA Sequence) SEQ ID No. 2 atgccgccac cccggaccgg ccgaggcctt ctctggctgg gtctggttct gagctccgtc 60 tgcgtcgccc tcggatccga aacgcaggcc aactcgacca cagatgctct gaacgttctt 120 ctcatcatcg tggatgacct gcgcccctcc ctgggctgtt atggggataa gctggtgagg 180 tccccaaata ttgaccaact ggcatcccac agcctcctct tccagaatgc ctttgcgcag 240 caagcagtgt gcgccccgag ccgcgtttct ttcctcactg gcaggagacc tgacaccacc 300 cgcctgtacg acttcaactc ctactggagg gtgcacgctg gaaacttctc caccatcccc 360 cagtacttca aggagaatgg ctatgtgacc atgtcggtgg gaaaagtctt tcaccctggg 420 atatcttcta accataccga tgattctccg tatagctggt cttttccacc ttatcatcct 480 tcctctgaga agtatgaaaa cactaagaca tgtcgagggc cagatggaga actccatgcc 540 aacctgcttt gccctgtgga tgtgctggat gttcccgagg gcaccttgcc tgacaaacag 600 agcactgagc aagccataca gttgttggaa aagatgaaaa cgtcagccag tcctttcttc 660 ctggccgttg ggtatcataa gccacacatc cccttcagat accccaagga atttcagaag 720 ttgtatccct tggagaacat caccctggcc cccgatcccg aggtccctga tggcctaccc 780 cctgtggcct acaacccctg gatggacatc aggcaacggg aagacgtcca agccttaaac 840 atcagtgtgc cgtatggtcc aattcctgtg gactttcagc ggaaaatccg ccagagctac 900 tttgcctctg tgtcatattt ggatacacag gtcggccgcc tcttgagtgc tttggacgat 960 cttcagctgg ccaacagcac catcattgca tttacctcgg atcatgggtg ggctctaggt 1020 gaacatggag aatgggccaa atacagcaat tttgatgttg ctacccatgt tcccctgata 1080 ttctatgttc ctggaaggac ggcttcactt ccggaggcag gcgagaagct tttcccttac 1140 ctcgaccctt ttgattccgc ctcacagttg atggagccag gcaggcaatc catggacctt 1200 gtggaacttg tgtctctttt tcccacgctg gctggacttg caggactgca ggttccacct 1260 cgctgccccg ttccttcatt tcacgttgag ctgtgcagag aaggcaagaa ccttctgaag 1320 cattttcgat tccgtgactt ggaagaggat ccgtacctcc ctggtaatcc ccgtgaactg 1380 attgcctata gccagtatcc ccggccttca gacatccctc agtggaattc tgacaagccg 1440 agtttaaaag atataaagat catgggctat tccatacgca ccatagacta taggtatact 1500 gtgtgggttg gcttcaatcc tgatgaattt ctagctaact tttctgacat ccatgcaggg 1560 gaactgtatt ttgtggattc tgacccattg caggatcaca atatgtataa tgattcccaa 1620 ggtggagatc ttttccagtt gttgatgcct 1650 (ApoE tandem repeat (ApoEII) DNA Sequence) SEQ ID No. 3 ctgagaaagc tgcggaagcg gctgctgctg aggaagctga gaaaaagact gctg 54 (Linker DNA Sequence) SEQ ID No. 4 ctgggagggg gaggatctgg cggagggga agtggcggcg gaggatcagg gggcggaggc 60 tct 63 (colDS Amino Acid Sequence) SEQ ID No. 5 MPPPRTGRGL LWLGLVLSSV CVALGSETQA NSTTDALNVL LIIVDDLRPS LGCYGDKLVR 60 SPNIDQLASH SLLFQNAFAQ QAVCAPSRVS FLTGRRPDTT RLYDFNSYWR VHAGNFSTIP 120 QYFKENGYVT MSVGKVFHPG ISSNHTDDSP YSWSFPPYHP SSEKYENTKT CRGPDGELHA 180 NLLCPVDVLD VPEGTLPDKQ STEQAIQLLE KMKTSASPFF LAVGYHKPHI PFRYPKEFQK 240 LYPLENITLA PDPEVPDGLP PVAYNPWMDI RQREDVQALN ISVPYGPIPV DFQRKIRQSY 300 FASVSYLDTQ VGRLLSALDD LQLANSTIIA FTSDHGWALG EHGEWAKYSN FDVATHVPLI 360 FYVPGRTASL PEAGEKLFPY LDPFDSASQL MEPGRQSMDL VELVSLFPTL AGLAGLQVPP 420 RCPVPSFHVE LCREGKNLLK HFRFRDLEED PYLPGNPREL IAYSQYPRPS DIPQWNSDKP 480 SLKDIKIMGY SIRTIDYRYT VWVGFNPDEF LANFSDIHAG ELYFVDSDPL QDHNMYNDSQ 540 GGDLFQLLMP 550 (Wild Type IDS Amino Acid Sequence) SEQ ID No. 6 MPPPRTGRGL LWLGLVLSSV CVALGSETQA NSTTDALNVL LIIVDDLRPS LGCYGDKLVR 60 SPNIDQLASH SLLFQNAFAQ QAVCAPSRVS FLTGRRPDTT RLYDFNSYWR VHAGNFSTIP 120 QYFKENGYVT MSVGKVFHPG ISSNHTDDSP YSWSFPPYHP SSEKYENTKT CRGPDGELHA 180 NLLCPVDVLD VPEGTLPDKQ STEQAIQLLE KMKTSASPFF LAVGYHKPHI PFRYPKEFQK 240 LYPLENITLA PDPEVPDGLP PVAYNPWMDI RQREDVQALN ISVPYGPIPV DFQRKIRQSY 300 FASVSYLDTQ VGRLLSALDD LQLANSTIIA FTSDHGWALG EHGEWAKYSN FDVATHVPLI 360 FYVPGRTASL PEAGEKLFPY LDPFDSASQL MEPGRQSMDL VELVSLFPTL AGLAGLQVPP 420 RCPVPSFHVE LCREGKNLLK HFRFRDLEED PYLPGNPREL IAYSQYPRPS DIPQWNSDKP 480 SLKDIKIMGY SIRTIDYRYT VWVGFNPDEF LANFSDIHAG ELYFVDSDPL QDHNMYNDSQ 540 GGDLFQLLMP 550 (ApoE tandem repeat (ApoEII) Amino Acid Sequence) SEQ ID No. 7 LRKLRKRLLL RKLRKRLL 18 (Linker Amino Acid Sequence) SEQ ID No. 8 LGGGGSGGGG SGGGGSGGGG S 21 -
-
- 1. Neufeld E F, Muenzer J. The Mucopolysaccharidoses. In: McGraw-Hill, editor. Lysosomal Disorders2001. p. 3421-52.
- 2. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. Journal of inherited metabolic disease. 2005; 28(6): 1011-7.
- 3. Poorthuis B J, Wevers R A, Kleijer W J, Groener J E, de Jong J G, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Human genetics. 1999; 105(1-2): 151-6. Epub 1999/09/10.
- 4. Wraith J E, Scarpa M, Beck M, Bodamer O A, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European journal of pediatrics. 2008; 167(3): 267-77. Epub 2007/11/27.
- 5. Cardone M, Polito V A, Pepe S, Mann L, D'Azzo A, Auricchio A, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Human molecular genetics. 2006; 15(7): 1225-36. Epub 2006/03/01.
- 6. Meikle P J, Hopwood J J, Clague A E, Carey W F. Prevalence of lysosomal storage disorders. Jama. 1999; 281(3): 249-54. Epub 1999/01/26.
- 7. Holt J B, Poe M D, Escolar M L. Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II. Pediatrics. 2011; 127(5): E1258-E65.
- 8. Eng C, Muenzer J, Wraith E, Beck M, Giugliani R, Harmatz P, et al. Clinical benefit of enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome). Molecular genetics and metabolism. 2007; 92(4): S18-S.
- 9. Muenzer J, Wraith J E, Beck M, Giugliani R, Harmatz P, Eng C M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genetics in Medicine. 2006; 8(8): 465-73.
- 10. Muenzer J, Beck M, Eng C M, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genetics in Medicine. 2011; 13(2): 95-101.
- 11. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce I A, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet journal of rare diseases. 2011; 6: 72. Epub 2011/11/09.
- 12. Brooks D A, Kakavanos R, Hopwood J J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends in molecular medicine. 2003; 9(10): 450-3. Epub 2003/10/15.
- 13. Wakabayashi T, Shimada Y, Akiyama K, Higuchi T, Fukuda T, Kobayashi H, et al. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II. Hum Gene Ther. 2015. Epub 2015/03/13.
- 14. Hinderer C, Katz N, Louboutin J P, Bell P, Yu H, Nayal M, et al. Delivery of an adeno-associated virus vector into CSF attenuates central nervous system disease in mucopolysaccharidosis type II mice. Hum Gene Ther. 2016. Epub 2016/08/12.
- 15. Motas S, Haurigot V, Garcia M, Marcó S, Ribera A, Roca C, et al. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight. 2016; 1(9).
- 16. Aldenhoven M, Jones S A, Bonney D, Borrill R E, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015; 21(6): 1106-9. Epub 2015/02/25.
- 17. Aldenhoven M, Wynn R F, Orchard P J, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015; 125(13): 2164-72. Epub 2015/01/28.
- 18. Boelens J J, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013; 121(19): 3981-7. Epub 2013/03/16.
- 19. Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. The Journal of pediatrics. 2009; 154(5): 733-7. Epub 2009/01/27.
- 20. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith J E. Long-term follow-up following bone marrow transplantation for Hunter disease. Journal of inherited metabolic disease. 1999; 22: 638-48.
- 21. Visigalli I, Delai S, Politi L S, Di Domenico C, Cerri F, Mrak E, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood. 2010; 116(24): 5130-9. Epub 2010/09/18.
- 22. Biffi A, Visigalli I. Hematopoietic Stem Cell Gene Therapy for Lysosomal Storage Disorders: Expected Benefits and Limitations. Stem Cells Biol Reg. 2013: 127-38.
- 23. Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. The Journal of clinical investigation. 2004; 113(8): 1118-29. Epub 2004/04/16.
-
- 24. Langford-Smith A, Wilkinson F L, Langford-Smith K J, Holley R J, Sergijenko A, Howe S J, et al. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Molecular therapy : the journal of the American Society of Gene Therapy. 2012; 20(8): 1610-21. Epub 2012/05/02.
- 25. Sergijenko A, Langford-Smith A, Liao A Y, Pickford C E, McDermott J, Nowinski G, et al. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Molecular therapy : the journal of the American Society of Gene Therapy. 2013; 21(10): 1938-49. Epub 2013/06/12.
- 26. Pardridge W M. Molecular biology of the blood-brain barrier. Molecular biotechnology. 2005; 30(1): 57-70. Epub 2005/04/05.
- 27. Pardridge W M. Targeting neurotherapeutic agents through the blood-brain barrier. Archives of neurology. 2002; 59(1): 35-40. Epub 2002/01/16.
- 28. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity T L. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. The Journal of clinical investigation. 1998; 101(5): 1084-93. Epub 1998/04/16.
- 29. Sorrentino N C, D'Orsi L, Sambri I, Nusco E, Monaco C, Spampanato C, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. Embo Mol Med. 2013; 5(5): 675-90. Epub 2013/04/10.
- 30. Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E, Adame A, et al. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. The Journal of biological chemistry. 2014; 289(25): 17917-31. Epub 2014/05/16.
- 31. Spencer B J, Verma I M. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A. 2007; 104(18): 7594-9. Epub 2007/04/28.
- 32. Bockenhoff A, Cramer S, Wolte P, Knieling S, Wohlenberg C, Gieselmann V, et al. Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014; 34(9): 3122-9. Epub 2014/02/28.
- 33. Wang D, El-Amouri S S, Dai M, Kuan CY, Hui D Y, Brady R O, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U S A. 2013; 110(8): 2999-3004. Epub 2013/02/06.
- 34. Bigger B W, Siapati E K, Mistry A, Waddington S N, Nivsarkar M S, Jacobs L, et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene therapy. 2006; 13(2): 117-26.
- 35. Siapati E K, Bigger B W, Miskin J, Chipchase D, Parsley K L, Mitrophanous K, et al. Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Molecular Therapy. 2005; 12(3): 537-46.
- 36. Kuroda H, Kutner R H, Bazan N G, Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 2009; 157(2): 113-21.
- 37. Lu J Z, Hui E K, Boado R J, Pardridge W M. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjugate chemistry. 2010; 21(1): 151-6. Epub 2009/12/17.
- 38. Holley R J, Deligny A, Wei W, Watson H A, Ninonuevo M R, Dagalv A, et al. Mucopolysaccharidosis Type I, Unique Structure of Accumulated Heparan Sulfate and Increased N-Sulfotransferase Activity in Mice Lacking alpha-L-iduronidase. Journal of Biological Chemistry. 2011; 286(43): 37515-24.
- 39. Nolan T, Hands R E, Bustin S A. Quantification of mRNA using real-time RT-PCR. Nature protocols. 2006; 1(3): 1559-82.
- 40. Wilkinson F L, Holley R J, Langford-Smith K J, Badrinath S, Liao A, Langford-Smith A, et al. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PloS one. 2012; 7(4): e35787. Epub 2012/05/05.
- 41. Jiang L, O'Leary C, Kim H A, Parish C L, Massalas J, Waddington J L, et al. Motor and behavioral phenotype in conditional mutants with targeted ablation of cortical D1 dopamine receptor-expressing cells. Neurobiology of disease. 2015; 76: 137-58. Epub 2015/02/17.
- 42. O'Tuathaigh C M P, Babovic D, O'Sullivan G J, Clifford J J, Tighe O, Croke D T, et al. Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia
risk gene neuregulin 1. Neuroscience. 2007; 147(1): 18-27.
Claims (26)
1. A nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence.
2. The nucleic acid as claimed in claim 1 , further comprising an intervening linker sequence located between the IDS sequence and the ApoEII sequence.
3. The nucleic acid of claim 1 , wherein the IDS sequence comprises a codon-optimised sequence of the wild-type IDS sequence.
4. The nucleic acid of claim 1 , wherein the repeat of the ApoEII sequence is in the form of a tandem repeat.
5. The nucleic acid of claim 1 , wherein the IDS sequence comprises the sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 or a derivative sequence having at least 90% homology thereof, or the ApoEII sequence comprises one or more sequences according to SEO ID NO: 3 or a derivative sequence having at least 95% homology thereof.
6. (canceled)
7. The nucleic acid of claim 2 , wherein the intervening linker sequence comprises the sequence according to SEQ ID NO: 4 or a derivative sequence having at least 95% homology thereof.
8. The nucleic acid of claim 2 , wherein the nucleic acid is incorporated in a gene therapy vector.
9. The nucleic acid of claim 8 , wherein the vector is a lentiviral vector.
10. The nucleic acid of claim 1 , wherein the nucleic acid is transduced in one or more haematopoietic stem and progenitor cells (HSPCs).
11. The nucleic acid of claim 1 , for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.
12. The nucleic acid of claim 11 , wherein the disease or condition comprises mucopolysaccharidosis type 11 (MPS 11) or Hunters syndrome.
13. A composition comprising:
a) a first moiety comprising iduronate-2-sulfatase (IDS); and
b) a second moiety comprising a repeat of Apolipoprotein E (ApoE11).
14. The composition of claim 13 , wherein the repeat of Apolipoprotein ApoEII is in the form of a tandem repeat.
15. The composition of claim 13 , wherein the first and second moiety have an intervening linker moiety located there between.
16. The composition of claim 13 , wherein the amino acid sequence of the first moiety comprises the sequence according to SEQ ID NO: 5 or a derivative sequence having at least 90% homology thereof, or the amino acid sequence of the second moiety comprise one or more sequences according to SEO ID NO: 7 or a derivative sequence having at least 95% homology thereof.
17. (canceled)
18. The composition of claim 15 , wherein the amino acid sequence of the intervening linker moiety comprise the sequence according to SEQ ID NO: 8 or a derivative sequence having at least 95% homology thereof.
19. The composition of claim 1 , for use in the treatment, management, retardation of progression or normalisation of development of a disease or condition attributable to iduronate-2-sulfatase (IDS) deficiency.
20. The composition of claim 19 , wherein the disease or condition comprises mucopolysaccharidosis type II (MPS II) or Hunters syndrome.
21. Haematopoietic stem and progenitor cells (HSPCs) for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysaccharidosis type II (MPS II) in an individual, wherein the HSPCs have been removed from the patient, transduced ex vivo with the nucleic acid claimed in claim 1 , and the transduced HSPCs administered to the individual.
22. A method for delivering a deficient iduronate-2-sulfatase (IDS) protein into the brain across the blood brain barrier in an individual suffering from a condition resulting from the deficiency in the protein, the composition comprising a viral vector comprising the gene sequence coding for the deficient protein tethered to a tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, wherein the vector is transduced, ex vivo, with a population of haematopoietic stem and progenitor cells (HSPCs) and the transduced HSPCs administered to the individual where they express higher physiological levels of the deficient protein which are sufficient to cross the blood brain barrier.
23. The method of claim 22 , wherein vector comprises a sequence for a flexible linker between the gene sequence coding for the deficient protein and the tandem repeat of the Apolipoprotein E (ApoEII) gene sequence, or the ApoEII tandem repeat gene sequence comprises the sequence according to SEO ID NO: 3 or variant sequences having up to 95% homology thereof, or the flexible linker sequence comprises the sequence according to SEO ID NO: 4 or variant sequences having up to 95% homology thereof.
24.-25. (canceled)
26. The method of claim 23 , wherein the HSPCs are autologous.
27. A combination of a nucleic acid comprising an iduronate-2-sulfatase (IDS) gene sequence and a repeat of the Apolipoprotein E (ApoEII) gene sequence and one or more haematopoietic stem and progenitor cells (HSPCs), wherein the nucleic acid is capable of transducing the HSPCs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/086,719 US20230390340A1 (en) | 2017-02-07 | 2022-12-22 | Gene therapy |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1701968.8 | 2017-02-07 | ||
GBGB1701968.8A GB201701968D0 (en) | 2017-02-07 | 2017-02-07 | Gene therapy |
PCT/GB2018/050347 WO2018146473A1 (en) | 2017-02-07 | 2018-02-07 | Gene therapy |
US201916484311A | 2019-08-07 | 2019-08-07 | |
US18/086,719 US20230390340A1 (en) | 2017-02-07 | 2022-12-22 | Gene therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/484,311 Division US11701390B2 (en) | 2017-02-07 | 2018-02-07 | Gene therapy |
PCT/GB2018/050347 Division WO2018146473A1 (en) | 2017-02-07 | 2018-02-07 | Gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230390340A1 true US20230390340A1 (en) | 2023-12-07 |
Family
ID=58462471
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/484,311 Active 2039-05-09 US11701390B2 (en) | 2017-02-07 | 2018-02-07 | Gene therapy |
US18/086,719 Pending US20230390340A1 (en) | 2017-02-07 | 2022-12-22 | Gene therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/484,311 Active 2039-05-09 US11701390B2 (en) | 2017-02-07 | 2018-02-07 | Gene therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US11701390B2 (en) |
EP (2) | EP3960188A1 (en) |
JP (1) | JP7237364B2 (en) |
ES (1) | ES2895263T3 (en) |
GB (1) | GB201701968D0 (en) |
WO (1) | WO2018146473A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201925236A (en) | 2017-10-02 | 2019-07-01 | 美商戴納立製藥公司 | Fusion proteins comprising enzyme replacement therapy enzymes |
WO2024096738A1 (en) | 2022-11-01 | 2024-05-10 | Erasmus University Medical Center Rotterdam | Gene therapy constructs for metabolic disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005056026A1 (en) | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
US10227387B2 (en) | 2011-05-18 | 2019-03-12 | Children's Hospital Medical Center | Targeted delivery of proteins across the blood-brain barrier |
JP2015500800A (en) | 2011-12-01 | 2015-01-08 | アンジオケム インコーポレーテッド | Targeted iduronic acid-2-sulfatase compound |
WO2016077356A2 (en) * | 2014-11-10 | 2016-05-19 | Synageva Biopharma Corp. | Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof |
-
2017
- 2017-02-07 GB GBGB1701968.8A patent/GB201701968D0/en not_active Ceased
-
2018
- 2018-02-07 US US16/484,311 patent/US11701390B2/en active Active
- 2018-02-07 EP EP21187825.1A patent/EP3960188A1/en active Pending
- 2018-02-07 WO PCT/GB2018/050347 patent/WO2018146473A1/en unknown
- 2018-02-07 JP JP2019542703A patent/JP7237364B2/en active Active
- 2018-02-07 ES ES18705462T patent/ES2895263T3/en active Active
- 2018-02-07 EP EP18705462.2A patent/EP3579849B1/en active Active
-
2022
- 2022-12-22 US US18/086,719 patent/US20230390340A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200000854A1 (en) | 2020-01-02 |
US11701390B2 (en) | 2023-07-18 |
GB201701968D0 (en) | 2017-03-22 |
EP3579849B1 (en) | 2021-09-08 |
ES2895263T3 (en) | 2022-02-18 |
WO2018146473A1 (en) | 2018-08-16 |
JP2020506714A (en) | 2020-03-05 |
EP3579849A1 (en) | 2019-12-18 |
JP7237364B2 (en) | 2023-03-13 |
EP3960188A1 (en) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gleitz et al. | Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms | |
US20230390340A1 (en) | Gene therapy | |
AU2016273343B2 (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
JP7037574B2 (en) | Composition useful for the treatment of spinal muscular atrophy | |
Biffi et al. | Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells | |
JP6066902B2 (en) | Vectors and sequences for treatment of disease | |
EP3533877A2 (en) | Viral vector for the targeted transfer of genes in the brain and spinal cord | |
TW201919676A (en) | Gene therapy for treating mucopolysaccharidosis type II | |
US20230332112A1 (en) | Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders | |
Penon-Portmann et al. | Current and new therapies for mucopolysaccharidoses | |
KR20190139951A (en) | Treatment of Mucopolysaccharide Type II with Recombinant Human Iduronate-2 Sulfatase (IDS) Produced by Human Neurons or Glial Cells | |
Poletto et al. | Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases | |
US20230295658A1 (en) | Compositions and methods for in vivo gene transfer | |
Ellison et al. | Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy | |
RU2748383C1 (en) | METHOD FOR THERAPY FOR TAY-SACHS DISEASE AND SANDHOFF DISEASE USING GENETICALLY MODIFIED HUMAN MESENCHYMAL STEM CELLS WITH OVEREXPRESSION OF β-HEXOSAMINIDASE A | |
WO2024096738A1 (en) | Gene therapy constructs for metabolic disorders | |
EP4426847A1 (en) | Compositions and methods for treating metachromatic leukodystrophy disease and related disorders | |
WO2022011099A1 (en) | Modified hexosaminidase and uses thereof | |
BR112017025892B1 (en) | ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS | |
Stok et al. | 881. Induction of Immunotolerance and Sustained Expression of ASA by Single Intravenous Injection of AAV Vector in Neonatal Immunocompetent Mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF MANCHESTER, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIGGER, BRIAN;GLEITZ, HELENE;SIGNING DATES FROM 20190819 TO 20190904;REEL/FRAME:064650/0026 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |